0001477932-15-005055.txt : 20150813 0001477932-15-005055.hdr.sgml : 20150813 20150813152753 ACCESSION NUMBER: 0001477932-15-005055 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20150813 DATE AS OF CHANGE: 20150813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RenovaCare, Inc. CENTRAL INDEX KEY: 0001016708 STANDARD INDUSTRIAL CLASSIFICATION: OIL AND GAS FIELD EXPLORATION SERVICES [1382] IRS NUMBER: 980170247 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-30156 FILM NUMBER: 151050411 BUSINESS ADDRESS: STREET 1: 430 PARK AVE. STREET 2: SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (800) 755-5815 MAIL ADDRESS: STREET 1: 430 PARK AVE. STREET 2: SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: Janus Resources, Inc. DATE OF NAME CHANGE: 20110110 FORMER COMPANY: FORMER CONFORMED NAME: ENTHEOS TECHNOLOGIES INC DATE OF NAME CHANGE: 20001002 FORMER COMPANY: FORMER CONFORMED NAME: WHATSONLINE COM INC DATE OF NAME CHANGE: 19990722 10-Q 1 rcar_10q.htm FORM 10-Q rcar_10q.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2015

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________ to ___________ 

 

Commission file number 000-30156

 

RENOVACARE, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

98-0384030

(State or other jurisdiction of incorporation)

(I.R.S. Employer Identification No.)

 

430 Park Avenue

Suite 702

New York, NY 10022

(Address of principal executive offices)

 

800-755-5815

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. 

 

Large accelerated filer 

¨

Accelerated filer 

¨

Non-accelerated filer 

¨

Smaller reporting company 

x

 

Indicate by check mark whether the registrant is a shell company (as defined in 12b-2 of the Exchange Act): Yes ¨ No x

 

As of August 13, 2015, the registrant had 67,781,193 shares of its common stock, par value $0.0001 per share, issued and outstanding.

 

 

 

RENOVACARE, INC.

 

FORM 10-Q

For The Quarter Ended June 30, 2015

 

TABLE OF CONTENTS

 

Page #

PART I - FINANCIAL INFORMATION

Item 1. 

Financial Statements 

3

Consolidated Balance Sheets 

3

Consolidated Statements of Operations 

4

Consolidated Statements of Cash Flows 

5

Notes to Consolidated Financial Statements 

6

Item 2. 

Management’s Discussion and Analysis of Financial Condition and Results of Operations 

13

Item 3. 

Quantitative and Qualitative Disclosures About Market Risk 

18

Item 4. 

Controls and Procedures 

19

PART II - OTHER INFORMATION

 

Item 1. 

Legal Proceedings 

20

Item 1A. 

Risk Factors 

20

Item 2. 

Unregistered Sales of Equity Securities and Use of Proceeds 

20

Item 6. 

Exhibits 

20

Signatures 

21

 

 
2
 

 

PART I

 

Item 1. Financial Statements

 

RENOVACARE, INC.

CONSOLIDATED BALANCE SHEETS

 

 

 

June 30,

 

 

December 31,

 

 

 

2015

 

 

2014

 

 

 

(unaudited)

 

 

 

ASSETS

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Cash and cash equivalents 

 

$ 1,162,565

 

 

$ 683,098

 

Prepaid expenses 

 

 

29,317

 

 

 

7,448

 

Total current assets

 

 

1,191,882

 

 

 

690,546

 

 

 

 

 

 

 

 

 

 

Intangible assets 

 

 

152,854

 

 

 

162,854

 

Total assets

 

$ 1,344,736

 

 

$ 853,400

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses 

 

$ 14,062

 

 

$ 6,182

 

Accounts payable and accrued expenses - related parties 

 

 

41,925

 

 

 

7,255

 

Contract and contribution payable 

 

 

105,500

 

 

 

187,500

 

Total current liabilities

 

 

161,487

 

 

 

200,937

 

 

 

 

 

 

 

 

 

 

Long term liabilities

 

 

 

 

 

 

 

 

Contract and contribution payable, less current portion 

 

 

159,375

 

 

 

178,125

 

 

 

 

 

 

 

 

 

 

Total liabilities

 

 

320,862

 

 

 

379,062

 

 

 

 

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Preferred stock: $0.0001 par value: Authorized: 10,000,000 shares Issued and outstanding: nil 

 

 

-

 

 

 

-

 

Common stock: $0.00001 par value: Authorized: 500,000,000 shares 

 

 

 

 

 

 

 

 

Issued and outstanding: 67,585,122 and 66,575,122 shares 

 

 

676

 

 

 

666

 

Additional paid-in capital 

 

 

9,159,513

 

 

 

8,128,860

 

Accumulated deficit 

 

 

(8,136,315 )

 

 

(7,655,188

Total stockholders’ equity

 

 

1,023,874

 

 

 

474,338

 

Total liabilities and stockholders’ equity

 

$ 1,344,736

 

 

$ 853,400

 

 

(The accompanying notes are an integral part of these consolidated financial statements)

 

 
3
 

 

RENOVACARE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

 

 

 

For the Three Months

Ended June 30,

For the Six Months

Ended June 30,

 

 

2015

 

 

2014

 

 

2015

 

 

2014

 

Revenue

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses 

 

 

50,235

 

 

 

65,000

 

 

 

111,625

 

 

 

65,000

 

General and administrative expenses 

 

 

165,695

 

 

 

268,682

 

 

 

369,502

 

 

 

536,703

 

Total operating expenses 

 

 

215,930

 

 

 

333,682

 

 

 

481,127

 

 

 

601,703

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Net loss

 

$ (215,930 )

 

$ (333,682 )

 

$ (481,127 )

 

$ (601,703 )
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share - basic and diluted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per common share 

 

$ (0.00 )

 

$ (0.01 )

 

$ (0.01 )

 

$ (0.01 )
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding 

 

 

66,852,595

 

 

 

66,575,122

 

 

 

66,714,122

 

 

 

63,575,122

 

 

(The accompanying notes are an integral part of these consolidated financial statements)

 

 
4
 

 

RENOVACARE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

 

 

 

For the Six Months

Ended June 30,

 

 

 

2015

 

 

2014

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss 

 

$ (481,127 )

 

$ (601,703 )

Adjustments to reconcile net loss to net cash flows from operating activities: 

 

 

 

 

 

 

 

 

Impairment loss 

 

 

10,000

 

 

 

-

 

Stock based compensation expense 

 

 

20,663

 

 

 

19,355

 

Stock based consulting expense 

 

 

-

 

 

 

195,333

 

Changes in operating assets and liabilities: 

 

 

 

 

 

 

 

 

Receivables 

 

 

-

 

 

 

(1,600 )

Prepaid expenses 

 

 

(21,869 )

 

 

(23,107 )

Accounts payable and accrued expenses 

 

 

7,880

 

 

 

70,972

 

Accounts payable and accrued expenses - related party 

 

 

34,670

 

 

 

-

 

Contract and contributions payable 

 

 

(100,750 )

 

 

-

 

Net cash flows from operating activities

 

 

(530,533 )

 

 

(340,750 )
 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Proceeds from sale of common stock plus warrants 

 

 

1,010,000

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in cash and cash equivalents

 

 

479,467

 

 

 

(340,750 )

Cash and cash equivalents, beginning of period 

 

 

683,098

 

 

 

1,508,843

 

Cash and cash equivalents, end of period 

 

$ 1,162,565

 

 

$ 1,168,093

 

 

(The accompanying notes are an integral part of these consolidated financial statements)

 

 
5
 

 

RENOVACARE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

1. Organization, Nature and Continuance of Operations

 

RenovaCare, Inc., together with its wholly owned subsidiary (the “Company”), focuses on the acquisition, research, development and, if warranted, commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications. The Company was previously involved in the exploration and development of both mineral exploration properties and oil and gas properties. 

 

On July 12, 2013, the Company, through its wholly owned subsidiary, RenovaCare Sciences Corp. (“RenovaCare Sciences”), completed the acquisition of its flagship technology, a treatment methodology for skin isolation, spraying and associated equipment for the regeneration of human skin cells (the “SkinGunTM”), along with the associated United States patent applications and two (2) foreign patents, the first of which expires on August 22, 2027 and the second of which expires on April 26, 2031. 

 

The Company has recently incurred net operating losses and operating cash flow deficits. As of June 30, 2015, the Company’s total accumulated deficit is $9.2 million. The Company does not currently generate revenues and will continue to incur losses from operations and operating cash flow deficits in the future. Management believes that the Company’s cash and cash equivalent balances, anticipated cash flows from operations and other external sources of capital will be sufficient to meet the Company’s cash requirements through June 30, 2016. The future of the Company after June 30, 2016 will depend in large part on its ability to successfully raise capital from external sources to fund operations and/or, generate revenue and cash flow from operations. 

 

2. Significant Accounting Policies

 

Basis of Presentation and Principles of Accounting

 

The interim consolidated financial statements included herein have been prepared by the Company, without audit, in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) pursuant to Part 210 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to such SEC rules and regulations, although the Company believes that the disclosures included are adequate to make the information presented not misleading. 

 

In management’s opinion, the unaudited consolidated financial statements contained herein reflect all adjustments, consisting solely of normal recurring items, which are necessary for the fair presentation of the Company’s financial position, results of operations, and cash flows on a basis consistent with that of the Company’s prior audited consolidated financial statements. The Company has evaluated information about subsequent events that became available to us through the date the financial statements were issued. This information relates to events, transactions or changes in circumstances that would require us to adjust the amounts reported in the financial statements or to disclose information about those events, transactions or changes in circumstances. The results of operations for interim periods may not be indicative of results to be expected for the full fiscal year. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements, including the notes thereto for the year ended December 31, 2014, which may be found under the Company’s profile on EDGAR. 

 

Principles of Consolidation

 

These consolidated financial statements have been prepared in accordance with US GAAP and include the accounts of the Company and its wholly owned subsidiary, RenovaCare Sciences. All significant intercompany transactions and balances have been eliminated. RenovaCare Sciences was incorporated under the laws of the State of Nevada on June 12, 2013. 

 

 
6
 

 

Applicable Accounting Guidance

 

Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board’s Accounting Standards Codification. 

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) 605, Revenue Recognition. The new revenue recognition standard requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for interim and annual reporting periods beginning after December 15, 2017 and is to be applied retrospectively. The Company does not currently have any revenue. As such, ASU 2014-09 will not have any effect on the Company’s results of operations and financial position. If the Company begins generating revenue prior to the effective date of ASU 2014-09, it will evaluate the effect that ASU 2014-09 will have on its results of operations and financial position. 

 

Accounting Estimates

 

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results, as determined by future events, may differ from these estimates. 

 

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents may at times exceed federally insured limits. 

 

Fair Value of Financial Instruments

 

The carrying amounts for cash and cash equivalents and payables approximate fair value based on observable quoted prices for active markets - Level 1 inputs. 

 

Research and Development Costs

 

The Company intends to outsource its research and development efforts and expense related costs as incurred, including the cost of manufacturing product for testing, licensing fees and costs associated with planning and conducting clinical trials. The value ascribed to patents and other intellectual property acquired will be capitalized as it relates to particular research and development projects that may have alternative future uses. 

 

Intangible Assets

 

The intangible asset consists primarily of SkinGunTM technology that the Company acquired during 2013 and is recorded at cost. At the time of acquisition the technology had not reached technological feasibility. The amount capitalized is subject to impairment testing until completion or abandonment. Upon successful completion, a determination will be made as to the then useful life of the intangible asset, generally determined by the period in which substantially all of the cash flows are expected to be generated, and begin amortization. The Company tests the intangible asset for impairment at least annually or more frequently if impairment indicators exist after performing a qualitative analysis. Management has multiple criteria that it considers when performing the qualitative analysis. The results of this review are then weighed and prioritized. If the totality of the relevant events and circumstances indicate that the intangible asset is not impaired, additional impairment tests are not necessary. 

 

 
7
 

 

The Company assessed the following qualitative factors that could affect any change in the fair value of the intangible asset: analysis of the technology’s current phase, additional testing necessary to bring the technology to market, development of competing products, changes in projections caused by delays, changes in regulations, changes in the market for the technology and changes in cost projections to bring the technology to market. Based on a qualitative assessment, management concluded that a positive assertion can be made from the qualitative assessment that it is more likely than not that the intangible asset related to the SkinGunTM is not impaired. The Company did, however, determine that an intangible asset related to wound care technology, acquired during 2013, was impaired during the period ended March 31, 2015 and recorded an impairment loss (a component of research and development expenses) amounting to $10,000 which was equal to the amount capitalized. 

 

Stock Options

 

The Company measures all stock-based compensation awards using a fair value method on the date of grant and recognizes such expense in its consolidated financial statements over the requisite service period. The Company uses the Black-Scholes pricing model to determine the fair value of stock-based compensation awards on the date of grant. The Black-Scholes pricing model requires management to make assumptions regarding option lives, expected volatility, and risk free interest rates. 

 

Income Taxes

 

The Company recognizes income taxes on an accrual basis based on tax positions taken, or expected to be taken, in tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. Should they occur, the Company’s policy is to classify interest and penalties related to tax positions as interest expense. Since the Company’s inception, no such interest or penalties have been incurred. The Company did not record an income tax provision during the periods presented due to net taxable losses. 

 

Earnings (Loss) Per Share

 

The Company presents both basic and diluted earnings per share (“EPS”) amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. Potentially dilutive shares of common stock consisted of warrants to purchase shares of common stock (9,210,000 shares as of June 30, 2015 and 8,200,000 at December 31, 2014) and options to purchase shares of common stock (200,000 shares as of June 30, 2015 and 185,000 as of December 31, 2014). During the periods presented, potentially dilutive shares of common stock were not included in the computation of dilutive loss per share as to do so would be anti-dilutive. 

 

Related Party Transactions

 

A related party is generally defined as (i) any person who holds 10% or more of the Company’s securities and their immediate families; (ii) the Company’s management; (iii) someone who directly or indirectly controls, is controlled by or is under common control with the Company; or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. See “Note 7. Related Party Transactions,” for further discussion. 

 

 
8
 

 

3. Intangible Assets - Intellectual Property

 

On July 12, 2013, the Company, together with its wholly owned subsidiary, RenovaCare Sciences, entered into an asset purchase agreement with Dr. Jorg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlach’s rights, title and interest in the SkinGunTM. The Company plans to further the development of the SkinGunTM and, if commercially viable, bring the product to market. Acquisition related costs amounted to $52,852 and were capitalized together with the cash payment upon the closing of the transaction in July 2013 of $100,002. Additional costs capitalized during 2013, and which related to an option to evaluate a wound cap technology, amounted to $10,000. The Company allowed this option to expire, and during the period ended March 31, 2015 recorded an impairment loss amounting to $10,000, which was equal to the amount capitalized. Intangible assets amounted to $152,854 and $162,854 at June 30, 2015 and December 31, 2014, respectively. 

 

The asset purchase agreement was amended on June 9, 2014 (the “Amended APA”). Pursuant to the terms of the Amended APA, an additional $300,000 will be paid in four installments: (a) $100,000 on December 31, 2014; (b) $50,000 on December 31, 2015; (c) $50,000 on December 31, 2016; and (d) $100,000 on December 31, 2017. The Company paid the first installment of $100,000 in January 2015. At June 30, 2015, $50,000 of the amount payable to Dr. Gerlach was recorded as current liabilities and $150,000 was recorded as long-term liabilities in the accompanying consolidated balance sheet. 

 

As further consideration for the SkinGunTM, the Company issued to Dr. Gerlach a Series A Stock Purchase Warrant (the “Series A Warrant”) entitling him to purchase 1,200,000 shares (each a “Warrant Share”) of the Company’s common stock at an exercise price of $0.35 per share. Pursuant to the terms of the Amended APA, the Series A Warrant will vest in five equal installments of 240,000 shares on each of July 12, 2014, July 12, 2015, July 12, 2016, July 12, 2017 and July 12, 2018. Vesting will no longer be contingent on the achievement of certain milestones and on Dr. Gerlach’s continuing to provide consulting services to the Company, but instead on passage of time. Prior to September 9, 2014, the effective date of the Amended APA, the value of the Series A Warrant was recognized as consulting expenses over the vesting term. Effective September 9, 2014, the Company measured and expensed the value of the Series A Warrant in full and recorded this value as research and development costs. The fair value of each Warrant Share as of September 9, 2014, using the Black-Scholes option pricing model, was $0.91. 

 

Consulting expense associated with the Series A Warrant amounted to $0 during the three months ended June 30, 2015 (2014: $195,333). There were no research and development expense associated with the Series A Warrant during the three months ended June 30, 2015 and June 30, 2014. 

 

On May 1, 2015, the Company entered into a new option agreement (the “Option Agreement”) with Dr. Jorg Gerlach, pursuant to which the Company obtained a one-year exclusive option to evaluate a wound cap technology (the “Technology”), for the purpose of determining whether the Company would like to purchase or license the Technology. Pursuant to the terms of the Option Agreement, the Company will pay Dr. Gerlach a non-refundable fee of $24,000, payable in four quarterly installments of $6,000, with the first installment due on May 1, 2015. The $24,000 option payment was recognized as research and development expense during the period ended June 30, 2015. 

 

4. Common Stock Options

 

Approval of the 2013 Long-Term Incentive Plan

 

On June 20, 2013, the Board of Directors (the “Board”) adopted, subject to receiving shareholder approval, the 2013 Long-Term Incentive Plan (the “Incentive Plan”). The Incentive Plan provides for the issuance of stock options of up to 20,000,000 shares (subject to adjustment) of the Company’s common stock to officers, directors, key employees and consultants of the Company. Options granted to employees under the Incentive Plan, including directors and officers who are employees, may be incentive stock options or non-qualified stock options; options granted to others under the Incentive Plan are limited to non-qualified stock options. On November 15, 2013, shareholders owning a majority of the Company’s issued and outstanding shares approved the Incentive Plan. 

 

The Incentive Plan is administered by the Board or a committee designated by the Board. Subject to the provisions of the Incentive Plan, the Board has the authority to determine the officers, employees and consultants to whom options will be granted, the number of shares covered by each option, vesting rights and the terms and conditions of each option that is granted to them; however, no person may be granted in any of the Company’s fiscal year, options to purchase more than 2,000,000 shares under the Incentive Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the Incentive Plan are exercisable no later than ten years after the date of grant. 

 

 
9
 

 

The exercise price per share of common stock for options granted under the Incentive Plan will be the fair market value of the Company’s common stock on the date of grant, using the closing price of the Company’s common stock on the last trading day prior to the date of grant, except for incentive stock options granted to a holder of ten percent or more of the Company’s common stock, for whom the exercise price per share will not be less than 110% of the fair market value. No option can be granted under the Incentive Plan after June 20, 2023. 

 

On May 29, 2015, the Company appointed Patricia Jeanne Riley to its Scientific Advisory Board and issued Ms. Riley an option to purchase 7,500 shares of the Company’s common stock at a price of $1.43 per share, the closing price of the Company’s common stock as quoted on the OTCQB on May 28, 2015. On June 15, 2015, the Company appointed Dr. Steven Wang to its Scientific Advisory Board and issued Dr. Wang an option to purchase 7,500 shares of the Company’s common stock at a price of $1.25 per share, the closing price of the Company’s common stock as quoted on the OTCQB on June 12, 2015. The shares underlying the options may be exercised on a “cashless basis” using the formula contained therein and, subject to each individual’s continued service with the Company. The shares underlying the options vest on November 30, 2015 and December 15, 2015, respectively.

 

As of June 30, 2015, there were 19,800,000 shares available for grant. 

 

Stock Option Activity

 

The following table summarizes stock option activity for the period ended June 30, 2015: 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

Weighted

 

 

Remaining

 

 

Aggregate

 

 

Options

 

 

Average

 

 

Contractual

 

 

Intrinsic

 

 

Outstanding

 

 

Exercise Price

 

 

Life (Years)

 

 

Value

 

Balance January 1, 2015 

 

 

185,000

 

 

$ 0.83

 

 

 

9.12

 

 

$ 94,150

 

Options granted 

 

 

15,000

 

 

 

1.34

 

 

 

10.00

 

 

$ 0

 

Balance June 30, 2015 

 

 

200,000

 

 

$ 0.80

 

 

 

8.87

 

 

$ 94,150

 

Exercisable at June 30, 2015 

 

 

100,000

 

 

$ 0.81

 

 

 

8.71

 

 

$ 53,250

 

 

The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. There were 15,000 stock options granted during the three months ended June 30, 2015, 7,500 shares each to a member of the Company’s Scientific Advisory Board. The weighted-average fair value of stock options granted in 2015 was approximately $1.00 per share. The weighted average fair value of stock options granted during 2014 was $1.05 per share. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company’s historical experience. The risk-free interest rate is based on a U.S. treasury note with maturity similar to the option award’s expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The assumptions for volatility, expected life, dividend yield and risk-free interest rate for options granted are presented in the table below: 

 

2015

2014

Weighted average risk-free interest rate 

1.49 - 1.71%

1.43 - 1.62%

Expected life in years 

5.50

4.50 - 5.50

Weighted avg. expected volatility 

94.4%

99.5 - 105.3%

Expected dividend yield 

$0

$0

 

 
10
 

 

Stock option expense reflected in the consolidated statements of operations related to stock options issued to our non-employee scientific advisory board members and consultants are recognized at fair value using the Black-Scholes option-pricing model with weighted average assumptions described above. For the three months ended June 30, 2015 and 2014, stock-based compensation expense recognized from stock option awards granted to non-employees included in total stock-based compensation expense amounted to $1,896 and $0, respectively. For the six months ended June 30, 2015 and 2014, stock-based compensation expense recognized from stock option awards granted to non-employees included in total stock-based compensation expense amounted to $1,896 and $0, respectively. 

 

During the three months ended June 30, 2015, total stock-based compensation expense of $9,719 was recognized as general and administrative expenses. During the three months ended June 30, 2014, total stock-based compensation expense of $12,573 was recognized as general and administrative expenses. During the six months ended June 30, 2015, total stock-based compensation expense of $20,663 was recognized as general and administrative expenses. During the six months ended June 30, 2014, total stock-based compensation expense of $19,355 was recognized as general and administrative expenses. 

 

There were 100,000 stock options vested and 100,000 stock options unvested as of June 30, 2015. As of June 30, 2015, the Company had $13,046 of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized by June 15, 2020. 

 

The Company issues new shares when options are exercised. 

 

5. Common Stock 

 

On June 5, 2015, the Company entered into subscription agreements with five investors for the purchase and sale of an aggregate of 1,010,000 units of equity securities (the “Units”) at a price of $1.00 per Unit for total gross proceeds of $1,010,000. Each Unit consists of one share of common stock and one Series D Stock Purchase Warrant (the “Series D Warrants”) allowing the holder to purchase one share of the Company’s common stock at a price of $1.10 per share for a period of five years; the Series D Warrants contain a provision allowing the holder to exercise the Series D Warrant on a cashless basis as further set forth therein. 

 

The relative fair value of the common stock was estimated to be approximately $590,000 and the relative fair value of the Series D Warrants was estimated to be $420,000 as determined based on the relative fair value allocation of the proceeds received. The Series D Warrants were valued using the Black-Scholes option pricing model based on the following assumptions: risk free interest rate of 1.75%, contractual life of five years, expected volatility of 88.0% and a dividend yield of 0%. 

 

6. Commitments 

 

On August 1, 2013, the Company engaged Vector to assist the Company with identifying subject matter experts in the medical device and biotechnology industries and to assist the Company with its ongoing research, development and eventual commercialization of its Regeneration Technology (collectively, the “Services”). In consideration of the Services, the Company will pay Vector a monthly consulting fee of $5,000. 

 

In connection with the Company’s anticipated Section 510(k) submission of its proprietary SkinGunTM to the Food and Drug Administration, the Company has engaged StemCell System GmbH (“StemCell Systems”) to provide it with prototypes and related documents. Pursuant to this engagement the Company incurred expenses of $44,910 in the three months ended June 30, 2015. 

 

On September 25, 2014, the Company entered into a Charitable Grant Agreement with the University of Pittsburgh (the “University”), pursuant to which the Company committed to provide a charitable donation to the University in the aggregate amount of $75,000 (the “Grant”). The Company will pay the Grant in eight quarterly installments of $9,375, with the first payment made on or before October 2014 and the final payment to be made on or before July 31, 2016. Dr. Gerlach, from whom the Company purchased the SkinGunTM, is a professor at the University. At June 30, 2015, $37,500 of the amount payable to the University was recorded as current liabilities and $9,375 was recorded as long-term liabilities in the accompanying consolidated balance sheet. 

 

See also “Note 7. Related Party Transactions.” 

 

 
11
 

 

7. Related Party Transactions

 

As compensation for their service on the Board, Dr. Kirkland and Mr. Sierchio will receive an annual retainer of $6,000, payable in equal yearly installments in arrears and prorated for any partial years of service. 

 

For the three months ended June 30, 2015, directors’ and consulting fees payable to officers and directors of the Company were $3,000 (2014: $3,000). Legal fees paid or payable to one of the Company’s directors in the three months ended June 30, 2015 were $28,125 (2014: $27,820). For the six months ended June 30, 2015, directors’ and consulting fees paid or payable to officers and directors of the Company were $6,000 (2014: $6,000). Legal fees paid or payable to one of the Company’s directors in the six months ended June 30, 2015 were $67,105 (2014: $82,185). Amounts included in accounts payable and accrued expenses, and due to related parties, were $23,800 at June 30, 2015 and $36,080 as of December 31, 2014. 

 

8. Subsequent Events

 

On July 1, 2015, the Company appointed Dr. Richard Simman to its Scientific Advisory Board and issued Dr. Simman an option to purchase 7,500 shares of the Company’s common stock at a price of $1.34 per share, the closing price of the Company’s common stock as quoted on the OTCQB on June 30, 2015. The option may be exercised on a “cashless basis” using the formula contained therein and, subject to Dr. Simman’s continued service with the Company. The shares underlying the option vest on December 31, 2015. 

 

Subsequent to the period ended June 30, 2015, the Company issued to Dr. Jorg Gerlach 196,812 shares of its common stock uponthe cashless exercise of 240,000 vested shares included in the Series A Warrant issued to Dr. Gerlach pursuant to the asset purchase agreement entered into between the Company and Dr. Gerlach on July 12, 2013. 

 

 
12
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this Quarterly Report filed on Form 10-Q. This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors.

 

This discussion and analysis should be read in conjunction with the accompanying unaudited interim consolidated financial statements and related notes. The discussion and analysis of the financial condition and results of operations are based upon the unaudited interim consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of any contingent liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. On an on-going basis we review our estimates and assumptions. The estimates were based on historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results are likely to differ from those estimates under different assumptions or conditions, but we do not believe such differences will materially affect our financial position or results of operations. Critical accounting policies, the policies us believes are most important to the presentation of its financial statements and require the most difficult, subjective and complex judgments, are outlined below in “Critical Accounting Policies,” and have not changed significantly. 

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, as well as information relating to RenovaCare, Inc. and its subsidiaries that is based on management’s exercise of business judgment and assumptions made by and information currently available to management. Although forward-looking statements in this Quarterly Report on Form 10-Q reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. When used in this document and other documents, releases and reports released by us, the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “the facts suggest” and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect our current view of future events and are subject to certain risks and uncertainties as noted below. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results could differ materially from those anticipated in these forward-looking statements. Actual events, transactions and results may materially differ from the anticipated events, transactions or results described in such statements. Although we believe that our expectations are based on reasonable assumptions, we can give no assurance that our expectations will materialize. Many factors could cause actual results to differ materially from our forward looking statements and unknown, unidentified or unpredictable factors could materially and adversely impact our future results. We undertake no obligation and do not intend to update, revise or otherwise publicly release any revisions to our forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated events. Several of these factors include, without limitation: 

 

·

our ability to meet requisite regulations or receive regulatory approvals in the United States, and our ability to retain any regulatory approvals that we may obtain; and the absence of adverse regulatory developments in the United States and abroad; 

·

new entrance of competitive products or further penetration of existing products in our markets; 

·

the effect on us from adverse publicity related to our products or the company itself; and 

·

any adverse claims relating to our intellectual property. 

 

 
13
 

 

The safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, apply to forward-looking statements made by us. The reader is cautioned that no statements contained in this Form 10-Q should be construed as a guarantee or assurance of future performance or results. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors, including, without limitation, the risks described in this report and matters described in this report generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur. 

 

Overview

 

RenovaCare, Inc. (formerly Janus Resources, Inc.) (together with its wholly owned subsidiary, “RenovaCare” “the Company” “we” “us” and “our”) was incorporated under the laws of the State of Nevada and has an authorized capital of 500,000,000 shares of $0.00001 par value common stock, of which 67,781,193 shares are outstanding as of August 13, 2015, and 10,000,000 shares of $0.0001 par value preferred stock, of which none are outstanding. 

 

On January 7, 2014, we filed a Certificate of Amendment to Articles of Incorporation changing our name from “Janus Resources, Inc.” to “RenovaCare, Inc.” so as to more fully reflect our operations. The Financial Industry Regulatory Authority (“FINRA”) declared the name change effective as of January 9, 2014. In conjunction with the name change, we changed our stock symbol on the OTCQB from “JANI” to “RCAR”. 

 

Our principal executive offices are located at 430 Park Avenue, Suite 702, New York, NY 10022. Our telephone number is (800) 755-5815. 

 

As we are a smaller reporting company, we are not required to make certain disclosures otherwise required to be made in a Form 10-Q. 

 

Description of Business

 

We are focusing on the acquisition, research, development and, if warranted, commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications. On July 12, 2013, we, through our wholly owned subsidiary, RenovaCare Sciences Corp., completed the acquisition of our flagship technology, a treatment methodology for skin isolation, spraying and associated equipment for the regeneration of human skin cells (the “SkinGunTM”), along with the associated United States patent applications and two (2) foreign patents, the first of which expires on August 22, 2027 and the second of which expires on April 26, 2031. We effected the acquisition of the SkinGunTM through an asset purchase agreement with Dr. Gerlach (the “APA”). Pursuant to the terms of the APA, as amended on September 9, 2014, we paid Dr. Gerlach an initial sum of $100,000 and are obligated to pay him an additional $300,000 in four installments: (a) $100,000 on December 31, 2014; (b) $50,000 on December 31, 2015; (c) $50,000 on December 31, 2016; and (d) $100,000 on December 31, 2017. Additionally, we issued to Dr. Gerlach a Series A Warrant allowing him to purchase up to 1,200,000 shares of our common stock at a purchase price of $0.35 per share. 

 

The average adult human has a skin surface area of between 16 - 21 square feet, which protects all other organs against the external environment. When a person’s skin is assailed by trauma or exposed to extreme heat, the skin’s various layers may be destroyed and depending on the severity of the injury, might cause life-threatening conditions. Currently, severe trauma to the skin, such as second or third degree burns, requires surgical mesh-grafting of skin, whereby healthy skin is removed from one area of the patient’s body (a “donor site”) and implanted on the damaged area. While mesh grafting is often the method of choice, we believe there are significant deficiencies with this method. The surgical procedure to remove healthy skin from the donor site can be painful and leaves the patient with a new wound that must also be attended to. In many instances the aesthetic results are not satisfying, as the color of the skin from the donor site may not match the skin color of the damaged skin. Additionally, since the ratio between the size of the wound area and the size of the donor site is quite low, i.e. the size of the skin removed must be substantially equal in size to the size of the damaged skin, the mesh-grafting approach is in many cases limited. Donor and injury sites can take weeks to heal, requiring expensive hospital stays, ongoing wound dressing management, and ever-changing anti-infection strategies. 

 

 
14
 

 

We are currently evaluating the efficacy and potential of our SkinGunTM, in combination with our unique cell isolation method, in the treatment of tissue that has been subject to severe trauma such as second and third degree burns. In small scale clinical trials, the SkinGunTM and cell isolation methodology have shown the ability to regenerate a more natural and thicker skin. The SkinGunTM utilizes the patient’s own skin stem cells and is able to address much larger treatment areas and at the same time reduce the size of the donor site. Furthermore, we believe the SkinGunTM enables the effective treatment of other skin disorders with minimal scarring compared to skin grafting. 

 

In a clinical study of 19 patients with deep dermal wound burns to the face and neck conducted in Berlin, Germany prior to our purchase of the SkinGunTM, researchers stated that, “careful surgical debridement and consecutive application of CEA [cultured epithelial auto graft] suspensions using a spray technique results in excellent cosmetic outcomes compared with any other method.” The same researchers concluded that, “We refuse to perform a prospective randomized study with groups in which traditional skin grafting and/or wound healing are still applied for the therapy for deep dermal burns due to the excellent results in our study. The method of CEA spray application has become our standard of care for these indications. The faster wound closure, the promotion of spontaneous wound healing by keratinocyte application, as well as the preservation of donor sites are further advantages of the method.” (Hartmann MD, Bernd, et al, “Sprayed Cultured Epithelial Autografts for Deep Dermal Burns of the Face and Neck” Annals of Plastic Surgery, 58.1(2007): 70-73. Print. emphasis added). The CEA spray application used by the researchers in the publication refers to the SkinGunTM and related cell isolation methodology; Dr. Gerlach assisted in the study. 

 

The development of our SkinGunTM is in the early stage and we anticipate that we will be required to expend significant time and resources to further develop our technology and determine whether a commercially viable product can be developed. Research and development of new technologies involves a high degree of risk and there is no assurance that our development activities will result in a commercially viable product. The long-term profitability of our operations will be, in part, directly related to the cost and success of our development programs, which may be affected by a number of factors. 

 

Strategy

 

Our ultimate goal is to leverage the potential of our SkinGunTM, together with our cell isolation method, as cutting edge treatments in skin therapy. Before we can do so, however, there are a number of steps we must first take, including: 

 

·

initiating a series of clinical trials to determine the SkinGunTM’s efficacy for treating wounds and burns;

·

formalizing collaborations with universities and scientific partners; 

·

creating a network of clinical and research partners; and 

·

achieving Food and Drug Administration (the “FDA”) and other regulatory approval. 

 

Additionally, we will likely be required to raise significant capital in order to fund our ongoing research and development operations, and there is no guarantee that we will be able to raise on acceptable terms, if at all. 

 

 
15
 

 

Results of Operations

 

Three Months Ended June 30, 2015 versus June 30, 2014

 

 

 

 

For the Three Months Ended June 30,

 

 

 

 

 

 

 

2015

 

 

2014

 

 

$ change

 

 

% change

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development 

 

$ 50,235

 

 

$ 65,000

 

 

$ (14,765 )

 

 

22.7

 

General and administrative 

 

 

165,695

 

 

 

268,682

 

 

 

(102,987 )

 

 

(38.3 )

Net loss 

 

$ (215,930 )

 

$ (333,682 )

 

$ (117,752 )

 

 

(35.3 )

 

Six Months Ended June 30, 2015 versus June 30, 2014

 

 

 

For the Six Months Ended June 30,

 

 

 

 

 

 

 

2015

 

 

2014

 

 

$ change

 

 

% change

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development 

 

$ 111,625

 

 

$ 65,000

 

 

$ 46,625

 

 

 

71.7

 

General and administrative 

 

 

369,502

 

 

 

536,703

 

 

 

(167,201 )

 

 

(31.2 )

Net loss 

 

$ (481,127 )

 

$ (601,703 )

 

$ (120,576 )

 

 

(20.0 )

 

Operations

 

Our expenses consist primarily of research and development costs, professional fees and administrative costs. For the three months ended June 30, 2015 and 2014, research and development costs were $50,235 and $65,000, respectively; general and administrative expenses were $165,695 and $268,682, respectively. The research and development costs in the second quarter of 2015 related to the development of the SkinGunTM and the acquisition of an option on wound cap technology. The research and development costs in the second quarter of 2014 related to the development of the SkinGunTM. The decrease in general and administrative fees in the second quarter of 2015 of $102,987 was due primarily to a decrease in legal fees and consulting expenses of $48,386 and $55,424, respectively. 

 

As a result of the foregoing, net loss for the three months ended June 30, 2015 and 2014 was $(215,930) and $(333,682), respectively. 

 

For the six months ended June 30, 2015 and 2014, research and development costs were $111,625 and $65,000, respectively; general and administrative expenses were $369,502 and $536,703, respectively. The research and development costs in the six months ended June 30, 2015 related to the development of the SkinGunTM and the acquisition of an option on wound cap technology. The research and development costs in the six months ended June 30, 2014 related to the development of the SkinGunTM. The decrease in general and administrative fees in the six months ended June 30, 2015 of $167,201 was due primarily to a decrease in legal fees and consulting expenses of $50,908 and $176,439, respectively, offset in part by an increase in compensation and related expenses of $67,724.  

 

As a result of the foregoing, net loss for the six months ended June 30, 2015 and 2014 were $(481,127) and $(601,703), respectively. 

 

 
16
 

 

Liquidity and Capital Resources

 

We currently finance our activities primarily by the private placement of our equity securities. There is no assurance that equity funding will be accessible to us at the times and in the amounts required to fund our ongoing operations. There are many conditions beyond our control, which have a direct bearing on the level of investor interest in the purchase of our securities. On June 5, 2015 the Company entered into subscription agreements with five investors for the purchase and sale of an aggregate of 1,010,000 Units at a price of $1.00 per Unit for total gross proceeds of $1,010,00. Each Unit consists of one share of common stock and one Series D Warrant allowing the holder to purchase one share of the Company’s common stock at a price of $1.10 per share for a period of five years; the Series D Warrants contain a provision allowing the holder to exercise the Series D Warrant on a cashless basis as further set forth therein. We do not have any agreements or understandings with any person as to additional financing. 

 

At June 30, 2015, we had cash of $1,162,565 (December 2014: $683,098) and working capital of $1,030,395 (December 2014: $489,609). Total liabilities as of June 30, 2015 were $320,862 (December 2014: $379,062). 

 

Our consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America and applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As discussed in Note 1 to the consolidated financial statements, we have incurred recurring operating losses since inception of $9.2 million. We require additional funds to meet our obligations and maintain our operations. We have sufficient working capital to (i) pay our administrative and general operating expenses through June 30, 2016, and (ii) to conduct our preliminary research and development programs. Without sufficient cash flow from operations, we may need to obtain additional funds (presumably through equity offerings and/or debt borrowing) in order, if warranted, to implement additional research and development programs on our SkinGunTM

 

Cash Flow

 

Operating activities: We used cash of $530,533 for operating activities for the six months ended June 30, 2015 (2014: $340,750). We have financed our operations through the sale of our equity securities. 

 

Investing Activities: There were no investing activities during the three months ended June 30, 2015 and 2014. 

 

Financing Activities: On June 5, 2015, the Company entered into subscription agreements with five investors for the purchase and sale of an aggregate of 1,010,000 Units at a price of $1.00 per Unit for total gross proceeds of $1,010,000. Each Unit consists of one share of common stock and one Series D Warrant allowing the holder to purchase one share of the Company’s common stock at a price of $1.10 per share for a period of five years; the Series D Warrants contain a provision allowing the holder to exercise the Series D Warrant on a cashless basis as further set forth therein. The proceeds from the Offering will be used for general corporate purposes, including the continued research and development of the Company’s SkinGunTM and CellMistTM technologies and for working capital. There were no financing activities during the three months ended June 30, 2014.  

 

Dividends

 

We have neither declared nor paid any dividends on its common stock. We intend to retain our earnings to finance growth and expand our operations and do not anticipate paying any dividends on our common stock in the foreseeable future. 

 

Fair Value of Financial Instruments and Risks

 

Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of significant judgment, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair value. 

 

 
17
 

 

The carrying value of cash and cash equivalents and payables approximate their fair value because of the short-term nature of these instruments. 

 

Management is of the opinion that we are not exposed to significant interest or credit risks arising from these financial instruments. 

 

Market Risk Disclosures

 

We have not entered into derivative contracts either to hedge existing risks or for speculative purposes during or subsequent to the periods presented. 

 

Off-balance Sheet Arrangements and Contractual Obligations

 

We do not have any off-balance sheet arrangements or contractual obligations at June 30, 2015, and the subsequent period to August [], 2015, that are likely to have or are reasonably likely to have a material current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that have not been disclosed in our consolidated financial statements. 

 

Critical Accounting Policies

 

See “Note 2. Significant Accounting Policies” in the Notes to the Consolidated Financial Statements in this Form 10-Q. 

 

Related Party Transactions

 

Our proposed business raises potential conflicts of interests between certain of our officers and directors and us. Certain of our directors are employees or consultants to other companies in the healthcare industry and, to the extent that such other companies may participate in ventures in which we may participate, our directors may have a conflict of interest in negotiating and concluding terms regarding the extent of such participation. In the event that such a conflict of interest arises at a meeting of our directors, a director who has such a conflict will abstain from voting for or against the approval of such participation or such terms. Other than as indicated, we have no other procedures or mechanisms to deal with conflicts of interest. We are not aware of the existence of any conflict of interest as described herein. 

 

Other than as disclosed below, during the three months ended June 30, 2015 and 2014, and the subsequent period, none of our current directors, officers or principal shareholders, nor any family member of the foregoing, nor, to the best of our information and belief, any of our former directors, senior officers or principal shareholders, nor any family member of such former directors, officers or principal shareholders, has or had any material interest, direct or indirect, in any transaction, or in any proposed transaction which has materially affected or will materially affect us. 

 

For the three months ended June 30, 2015, directors’ and consulting fees payable to officers and directors of the Company were $3,000 (2014: $3,000). Legal fees paid or payable to one of the Company’s directors in the three months ended June 30, 2015 were $28,125 (2014: $27,820). For the six months ended June 30, 2015, directors’ and consulting fees paid or payable to officers and directors of the Company were $6,000 (2014: $6,000). Legal fees paid or payable to one of the Company’s directors in the six months ended June 30, 2015 were $67,105 (2014: $82,185). Amounts included in accounts payable and accrued expenses, and due to related parties, were $23,800 at June 30, 2015 and $36,080 as of December 31, 2014. 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not applicable. 

 

 
18
 

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

At the end of the period covered by this Quarterly Report on Form 10-Q for the three month period ended June 30, 2015, an evaluation was carried out under the supervision of and with the participation of our management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act). Based on that evaluation the CEO and the CFO have concluded that as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that: (i) information required to be disclosed by us in reports that it files or submits to the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in applicable rules and forms and (ii) material information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow for accurate and timely decisions regarding required disclosure. 

 

Changes in Internal Control over Financial Reporting

 

During the period covered by this report, there were no changes to internal control over financial reporting that materially affected or are reasonably likely to materially affect our internal control over financial reporting. 

 

 
19
 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

None 

 

Item 1A. Risk Factors

 

Smaller reporting companies are not required to provide the information required by this item. 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None 

 

Item 6. Exhibits

 

Exhibit Index

 

Exhibit No.

Description of Exhibit

3.1 

Articles of incorporation (Incorporated by reference to Exhibit 3.1 of the Form S-8 filed on October 3, 2003). 

3.2 

Articles of Incorporation, as amended (Incorporated by reference to the Form 8-K filed on January 10, 2011). 

3.3 

Articles of Incorporation, as amended (Incorporated by reference to the Form 8-K filed on January 10, 2014). 

3.4 

Bylaws (Incorporated by reference to Exhibit 3.2 of the Form S-8 filed on October 3, 2003). 

31.1 

Certification of Principal Executive Officer Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.* 

31.2 

Certification of Principal Financial Officer Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.* 

32.1 

Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* 

101.INS 

XBRL Instance Document** 

101.SCH 

XBRL Taxonomy Extension - Schema Document** 

101.CAL 

XBRL Taxonomy Extension - Calculation Linkbase Document** 

101.DEF 

XBRL Taxonomy Extension - Definition Linkbase Document** 

101.LAB 

XBRL Taxonomy Extension - Label Linkbase Document** 

101.PRE 

XBRL Taxonomy Extension - Presentation Linkbase Document** 

_______________  

* Filed herewith. 

 

** Furnished herewith. XBRL (eXtensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections. 

 

 
20
 

 

SIGNATURES

 

Pursuant to the requirements of Sections 13 or 15 (d) of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.  

 

RenovaCare, Inc.

(Registrant) 

 

Date: August 13, 2015 

By: 

 /s/ Rhonda B. Rosen 

Name: 

 Rhonda B. Rosen 

Title: 

 Chief Financial Officer (Principal Financial Officer) 

 

Date: August 13, 2015 

By: 

 /s/ Thomas Bold 

Name: 

Thomas Bold 

Title: 

Chief Executive Officer (Principal Executive Officer) 

 

  

21 


EX-31.1 2 rcar_ex311.htm CERTIFICATION rcar_ex311.htm

EXHIBIT 31.1

 

CERTIFICATION PURSUANT TO RULE 13A-14(A) OR RULE 15D-14(A)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

 

I, Thomas Bold, certify that: 

 

1. I have reviewed this quarterly report on Form 10-Q of RenovaCare, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: August 13, 2015 

By: 

/s/ Thomas Bold

Name: 

 Thomas Bold 

Title: 

 President and Chief Executive Officer 

(Principal Executive Officer) 

 

EX-31.2 3 rcar_ex312.htm CERTIFICATION rcar_ex312.htm

EXHIBIT 31.2

 

CERTIFICATION PURSUANT TO RULE 13A-14(A) OR RULE 15D-14(A)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

 

I, Rhonda B. Rosen, certify that: 

 

1. I have reviewed this quarterly report on Form 10-Q of RenovaCare, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: August 13, 2015 

By: 

/s/ Rhonda B. Rosen

Name: 

Rhonda B. Rosen  

Title: 

Chief Financial Officer 

(Principal Accounting Officer, Principal Financial Officer) 

 

EX-32.1 4 rcar_ex321.htm CERTIFICATION rcar_ex321.htm

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Section 1350 of Chapter 63 of Title 18 of the United States Code), the undersigned officers of RenovaCare, Inc. (the “Company”) do hereby certify with respect to the Quarterly Report of the Company on Form 10-Q for the period ended June 30, 2015 (the “Report”) that: 

 

(i) the Report filed by the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(ii) The information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of the Company on the dates and for the periods presented therein.

 

 

RENOVACARE, INC.

Date: August 13, 2015 

By: 

/s/ Thomas Bold

Name: 

Thomas Bold 

Title: 

President and Chief Executive Officer 

(Principal Executive Officer) 

 

Date: August 13, 2015 

By: 

/s/ Rhonda B. Rosen

Name: 

Rhonda B. Rosen 

Title: 

Chief Financial Officer 

(Principal Accounting Officer, Principal Financial Officer) 

 

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. 

 

EX-101.INS 5 rcar-20150630.xml XBRL INSTANCE DOCUMENT 0001016708 2014-01-01 2014-06-30 0001016708 2015-08-13 0001016708 2015-06-30 0001016708 2014-06-30 0001016708 us-gaap:DirectorMember rcar:LegalFeeMember 2014-01-01 2014-06-30 0001016708 2014-12-31 0001016708 2015-01-01 2015-06-30 0001016708 rcar:OfficersandDirectorsMember rcar:ConsultingfeesMember 2015-01-01 2015-06-30 0001016708 rcar:OfficersandDirectorsMember rcar:ConsultingfeesMember 2014-01-01 2014-06-30 0001016708 us-gaap:DirectorMember rcar:LegalFeeMember 2015-01-01 2015-06-30 0001016708 2013-12-31 0001016708 rcar:DrGerlachMember 2015-06-30 0001016708 2015-04-01 2015-06-30 0001016708 2014-04-01 2014-06-30 0001016708 us-gaap:MinimumMember 2015-01-01 2015-06-30 0001016708 us-gaap:MinimumMember 2014-01-01 2014-06-30 0001016708 us-gaap:MaximumMember 2015-01-01 2015-06-30 0001016708 us-gaap:MaximumMember 2014-01-01 2014-06-30 0001016708 rcar:OfficersandDirectorsMember rcar:ConsultingfeesMember 2015-04-01 2015-06-30 0001016708 rcar:OfficersandDirectorsMember rcar:ConsultingfeesMember 2014-04-01 2014-06-30 0001016708 us-gaap:DirectorMember rcar:LegalFeeMember 2015-04-01 2015-06-30 0001016708 us-gaap:DirectorMember rcar:LegalFeeMember 2014-04-01 2014-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 67781193 0.0001 0.0001 10000000 10000000 0 0 0 0 0.00001 0.00001 500000000 500000000 67585122 66575122 67585122 66575122 1162565 1168093 683098 1508843 152854 162854 195333 0 0 24000 19800000 19355 20663 9719 12573 100000 100000 13046 37500 50000 18750 150000 82185 6000 6000 67105 3000 3000 28125 27820 Renovacare, Inc. 0001016708 10-Q 2015-06-30 false --12-31 No No Yes Smaller Reporting Company Q2 2015 9200000 9210000 8200000 200000 185000 200000 185000 15000 100000 0.80 0.83 1.34 0.81 P9Y1M13D P8Y10M13D P8Y8M16D 94150 94150 0 53250 44910 10000 320862 379062 159375 178125 161487 200937 105500 187500 41925 7255 14062 6182 1344736 853400 152854 162854 1191882 690546 29317 7448 676 666 9159513 8128860 -8136315 -7655188 1023874 474338 1344736 853400 63575122 66714122 66852595 66575122 -0.01 -0.01 0.00 -0.01 -601703 -481127 -215930 -333682 601703 481127 215930 333682 536703 369502 165695 268682 65000 111625 50235 65000 -340750 -530533 -100750 34670 70972 7880 -23107 -21869 -1600 195333 19355 20663 10000 -340750 479467 1010000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">RenovaCare, Inc., together with its wholly owned subsidiary (the &#147;Company&#148;), focuses on the acquisition, research, development and, if warranted, commercialization of autologous (using a patient&#146;s own cells) cellular therapies that can be used for medical and aesthetic applications. The Company was previously involved in the exploration and development of both mineral exploration properties and oil and gas properties.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On July 12, 2013, the Company, through its wholly owned subsidiary, RenovaCare Sciences Corp. (&#147;RenovaCare Sciences&#148;), completed the acquisition of its flagship technology, a treatment methodology for skin isolation, spraying and associated equipment for the regeneration of human skin cells (the &#147;SkinGun<sup>TM</sup>&#148;), along with the associated United States patent applications and two (2) foreign patents, the first of which expires on August 22, 2027 and the second of which expires on April 26, 2031.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company has recently incurred net operating losses and operating cash flow deficits. As of June 30, 2015, the Company&#146;s total accumulated deficit is $9.2 million. The Company does not currently generate revenues and will continue to incur losses from operations and operating cash flow deficits in the future. Management believes that the Company&#146;s cash and cash equivalent balances, anticipated cash flows from operations and other external sources of capital will be sufficient to meet the Company&#146;s cash requirements through June 30, 2016. The future of the Company after June 30, 2016 will depend in large part on its ability to successfully raise capital from external sources to fund operations and/or, generate revenue and cash flow from operations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Basis of Presentation and Principles of Accounting</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The interim consolidated financial statements included herein have been prepared by the Company, without audit, in accordance with the rules and regulations of the Securities and Exchange Commission (&#147;SEC&#148;) pursuant to Part 210 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) have been condensed or omitted pursuant to such SEC rules and regulations, although the Company believes that the disclosures included are adequate to make the information presented not misleading.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In management&#146;s opinion, the unaudited consolidated financial statements contained herein reflect all adjustments, consisting solely of normal recurring items, which are necessary for the fair presentation of the Company&#146;s financial position, results of operations, and cash flows on a basis consistent with that of the Company&#146;s prior audited consolidated financial statements. The Company has evaluated information about subsequent events that became available to us through the date the financial statements were issued. This information relates to events, transactions or changes in circumstances that would require us to adjust the amounts reported in the financial statements or to disclose information about those events, transactions or changes in circumstances. The results of operations for interim periods may not be indicative of results to be expected for the full fiscal year. Therefore, these financial statements should be read in conjunction with the Company&#146;s audited financial statements, including the notes thereto for the year ended December 31, 2014, which may be found under the Company&#146;s profile on EDGAR.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Principles of Consolidation</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These consolidated financial statements have been prepared in accordance with US GAAP and include the accounts of the Company and its wholly owned subsidiary, RenovaCare Sciences. All significant intercompany transactions and balances have been eliminated. RenovaCare Sciences was incorporated under the laws of the State of Nevada on June 12, 2013.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Applicable Accounting Guidance</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board&#146;s Accounting Standards Codification.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In May 2014, the Financial Accounting Standards Board (&#147;FASB&#148;) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification (&#147;ASC&#148;) 605, Revenue Recognition. The new revenue recognition standard requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for interim and annual reporting periods beginning after December 15, 2017 and is to be applied retrospectively. The Company does not currently have any revenue. As such, ASU 2014-09 will not have any effect on the Company&#146;s results of operations and financial position. If the Company begins generating revenue prior to the effective date of ASU 2014-09, it will evaluate the effect that ASU 2014-09 will have on its results of operations and financial position.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Accounting Estimates</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results, as determined by future events, may differ from these estimates.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Cash and Cash Equivalents</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents may at times exceed federally insured limits.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Fair Value of Financial Instruments</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The carrying amounts for cash and cash equivalents and payables approximate fair value based on observable quoted prices for active markets &#150; Level 1 inputs.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Research and Development Costs</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company intends to outsource its research and development efforts and expense related costs as incurred, including the cost of manufacturing product for testing, licensing fees and costs associated with planning and conducting clinical trials. The value ascribed to patents and other intellectual property acquired will be capitalized as it relates to particular research and development projects that may have alternative future uses.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Intangible Assets</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The intangible asset consists primarily of SkinGun<sup>TM</sup><sub> </sub>technology that the Company acquired during 2013 and is recorded at cost. At the time of acquisition the technology had not reached technological feasibility. The amount capitalized is subject to impairment testing until completion or abandonment. Upon successful completion, a determination will be made as to the then useful life of the intangible asset, generally determined by the period in which substantially all of the cash flows are expected to be generated, and begin amortization. The Company tests the intangible asset for impairment at least annually or more frequently if impairment indicators exist after performing a qualitative analysis. Management has multiple criteria that it considers when performing the qualitative analysis. The results of this review are then weighed and prioritized. If the totality of the relevant events and circumstances indicate that the intangible asset is not impaired, additional impairment tests are not necessary.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company assessed the following qualitative factors that could affect any change in the fair value of the intangible asset: analysis of the technology&#146;s current phase, additional testing necessary to bring the technology to market, development of competing products, changes in projections caused by delays, changes in regulations, changes in the market for the technology and changes in cost projections to bring the technology to market. Based on a qualitative assessment, management concluded that a positive assertion can be made from the qualitative assessment that it is more likely than not that the intangible asset related to the SkinGun<sup>TM</sup> is not impaired. The Company did, however, determine that an intangible asset related to wound care technology, acquired during 2013, was impaired during the period ended March 31, 2015 and recorded an impairment loss (a component of research and development expenses) amounting to $10,000 which was equal to the amount capitalized.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Stock Options</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company measures all stock-based compensation awards using a fair value method on the date of grant and recognizes such expense in its consolidated financial statements over the requisite service period. The Company uses the Black-Scholes pricing model to determine the fair value of stock-based compensation awards on the date of grant. The Black-Scholes pricing model requires management to make assumptions regarding option lives, expected volatility, and risk free interest rates.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Income Taxes</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company recognizes income taxes on an accrual basis based on tax positions taken, or expected to be taken, in tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#146;s financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. Should they occur, the Company&#146;s policy is to classify interest and penalties related to tax positions as interest expense. Since the Company&#146;s inception, no such interest or penalties have been incurred. The Company did not record an income tax provision during the periods presented due to net taxable losses.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Earnings (Loss) Per Share</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company presents both basic and diluted earnings per share (&#147;EPS&#148;) amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. Potentially dilutive shares of common stock consisted of warrants to purchase shares of common stock (9,210,000 shares as of June 30, 2015 and 8,200,000 at December 31, 2014) and options to purchase shares of common stock (200,000 shares as of June 30, 2015 and 185,000 as of December 31, 2014). During the periods presented, potentially dilutive shares of common stock were not included in the computation of dilutive loss per share as to do so would be anti-dilutive.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Related Party Transactions</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A related party is generally defined as (i) any person who holds 10% or more of the Company&#146;s securities and their immediate families; (ii) the Company&#146;s management; (iii) someone who directly or indirectly controls, is controlled by or is under common control with the Company; or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. See &#147;Note 7. Related Party Transactions,&#148; for further discussion.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On July 12, 2013, the Company, together with its wholly owned subsidiary, RenovaCare Sciences, entered into an asset purchase agreement with Dr. Jorg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlach&#146;s rights, title and interest in the SkinGun<sup>TM</sup>. The Company plans to further the development of the SkinGun<sup>TM</sup> and, if commercially viable, bring the product to market. Acquisition related costs amounted to $52,852 and were capitalized together with the cash payment upon the closing of the transaction in July 2013 of $100,002. Additional costs capitalized during 2013, and which related to an option to evaluate a wound cap technology, amounted to $10,000. The Company allowed this option to expire, and during the period ended March 31, 2015 recorded an impairment loss amounting to $10,000, which was equal to the amount capitalized. Intangible assets amounted to $152,854 and $162,854 at June 30, 2015 and December 31, 2014, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The asset purchase agreement was amended on June 9, 2014 (the &#147;Amended APA&#148;). Pursuant to the terms of the Amended APA, an additional $300,000 will be paid in four installments: (a) $100,000 on December 31, 2014; (b) $50,000 on December 31, 2015; (c) $50,000 on December 31, 2016; and (d) $100,000 on December 31, 2017. The Company paid the first installment of $100,000 in January 2015. At June 30, 2015, $50,000 of the amount payable to Dr. Gerlach was recorded as current liabilities and $150,000 was recorded as long-term liabilities in the accompanying consolidated balance sheet.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As further consideration for the SkinGun<sup>TM</sup>, the Company issued to Dr. Gerlach a Series A Stock Purchase Warrant (the &#147;Series A Warrant&#148;) entitling him to purchase 1,200,000 shares (each a &#147;Warrant Share&#148;) of the Company&#146;s common stock at an exercise price of $0.35 per share. Pursuant to the terms of the Amended APA, the Series A Warrant will vest in five equal installments of 240,000 shares on each of July 12, 2014, July 12, 2015, July 12, 2016, July 12, 2017 and July 12, 2018. Vesting will no longer be contingent on the achievement of certain milestones and on Dr. Gerlach&#146;s continuing to provide consulting services to the Company, but instead on passage of time. Prior to September 9, 2014, the effective date of the Amended APA, the value of the Series A Warrant was recognized as consulting expenses over the vesting term. Effective September 9, 2014, the Company measured and expensed the value of the Series A Warrant in full and recorded this value as research and development costs. The fair value of each Warrant Share as of September 9, 2014, using the Black-Scholes option pricing model, was $0.91.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Consulting expense associated with the Series A Warrant amounted to $0 during the three months ended June 30, 2015 (2014: $195,333). There were no research and development expense associated with the Series A Warrant during the three months ended June 30, 2015 and June 30, 2014.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On May 1, 2015, the Company entered into a new option agreement (the &#147;Option Agreement&#148;) with Dr. Jorg Gerlach, pursuant to which the Company obtained a one-year exclusive option to evaluate a wound cap technology (the &#147;Technology&#148;), for the purpose of determining whether the Company would like to purchase or license the Technology. Pursuant to the terms of the Option Agreement, the Company will pay Dr. Gerlach a non-refundable fee of $24,000, payable in four quarterly installments of $6,000, with the first installment due on May 1, 2015. The $24,000 option payment was recognized as research and development expense during the period ended June 30, 2015.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Approval of the 2013 Long-Term Incentive Plan</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On June 20, 2013, the Board of Directors (the &#147;Board&#148;) adopted, subject to receiving shareholder approval, the 2013 Long-Term Incentive Plan (the &#147;Incentive Plan&#148;). The Incentive Plan provides for the issuance of stock options of up to 20,000,000 shares (subject to adjustment) of the Company&#146;s common stock to officers, directors, key employees and consultants of the Company. Options granted to employees under the Incentive Plan, including directors and officers who are employees, may be incentive stock options or non-qualified stock options; options granted to others under the Incentive Plan are limited to non-qualified stock options. On November 15, 2013, shareholders owning a majority of the Company&#146;s issued and outstanding shares approved the Incentive Plan.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Incentive Plan is administered by the Board or a committee designated by the Board. Subject to the provisions of the Incentive Plan, the Board has the authority to determine the officers, employees and consultants to whom options will be granted, the number of shares covered by each option, vesting rights and the terms and conditions of each option that is granted to them; however, no person may be granted in any of the Company&#146;s fiscal year, options to purchase more than 2,000,000 shares under the Incentive Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the Incentive Plan are exercisable no later than ten years after the date of grant.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The exercise price per share of common stock for options granted under the Incentive Plan will be the fair market value of the Company&#146;s common stock on the date of grant, using the closing price of the Company&#146;s common stock on the last trading day prior to the date of grant, except for incentive stock options granted to a holder of ten percent or more of the Company&#146;s common stock, for whom the exercise price per share will not be less than 110% of the fair market value. No option can be granted under the Incentive Plan after June 20, 2023.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On May 29, 2015, the Company appointed Patricia Jeanne Riley to its Scientific Advisory Board and issued Ms. Riley an option to purchase 7,500 shares of the Company&#146;s common stock at a price of $1.43 per share, the closing price of the Company&#146;s common stock as quoted on the OTCQB on May 28, 2015. On June 15, 2015, the Company appointed Dr. Steven Wang to its Scientific Advisory Board and issued Dr. Wang an option to purchase 7,500 shares of the Company&#146;s common stock at a price of $1.25 per share, the closing price of the Company&#146;s common stock as quoted on the OTCQB on June 12, 2015. The shares underlying the options may be exercised on a &#147;cashless basis&#148; using the formula contained therein and, subject to each individual&#146;s continued service with the Company. The shares underlying the options vest on November 30, 2015 and December 15, 2015, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2015, there were 19,800,000 shares available for grant.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Stock Option Activity</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following table summarizes stock option activity for the period ended June 30, 2015:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr> <td style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr> <td style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Remaining</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr> <td style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Contractual</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Intrinsic</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr> <td style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Life (Years)</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Value</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Balance January 1, 2015</font></td> <td style="width: 1%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">185,000</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.83</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9.12</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">94,150</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Options granted</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">15,000</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.34</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10.00</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Balance June 30, 2015</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.80</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.87</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">94,150</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable at June 30, 2015</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.81</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.71</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">53,250</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. There were 15,000 stock options granted during the three months ended June 30, 2015, 7,500 shares each to a member of the Company&#146;s Scientific Advisory Board. The weighted-average fair value of stock options granted in 2015 was approximately $1.00 per share. The weighted average fair value of stock options granted during 2014 was $1.05 per share. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company&#146;s historical experience. The risk-free interest rate is based on a U.S. treasury note with maturity similar to the option award&#146;s expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The assumptions for volatility, expected life, dividend yield and risk-free interest rate for options granted are presented in the table below:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="background-color: white"> <td nowrap="nowrap" style="vertical-align: bottom; width: 60%"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="vertical-align: bottom; width: 20%; border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td> <td style="vertical-align: top; width: 20%; border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2014</b></font></td></tr> <tr style="background-color: rgb(204,238,255)"> <td nowrap="nowrap" style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">Weighted average risk-free interest rate</font></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.49 &#150; 1.71%</font></td> <td style="vertical-align: top; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.43 &#150; 1.62%</font></td></tr> <tr style="background-color: White"> <td nowrap="nowrap" style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">Expected life in years</font></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">5.50</font></td> <td style="vertical-align: top; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">4.50 &#150; 5.50</font></td></tr> <tr style="background-color: rgb(204,238,255)"> <td nowrap="nowrap" style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">Weighted avg. expected volatility</font></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">94.4%</font></td> <td style="vertical-align: top; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">99.5 &#150; 105.3%</font></td></tr> <tr style="background-color: White"> <td nowrap="nowrap" style="vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend yield</font></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">$0</font></td> <td style="vertical-align: top; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">$0</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Stock option expense reflected in the consolidated statements of operations related to stock options issued to our non-employee scientific advisory board members and consultants are recognized at fair value using the Black-Scholes option-pricing model with weighted average assumptions described above. For the three months ended June 30, 2015 and 2014, stock-based compensation expense recognized from stock option awards granted to non-employees included in total stock-based compensation expense amounted to $1,896 and $0, respectively. For the six months ended June 30, 2015 and 2014, stock-based compensation expense recognized from stock option awards granted to non-employees included in total stock-based compensation expense amounted to $1,896 and $0, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended June 30, 2015, total stock-based compensation expense of $9,719 was recognized as general and administrative expenses. During the three months ended June 30, 2014, total stock-based compensation expense of $12,573 was recognized as general and administrative expenses. During the six months ended June 30, 2015, total stock-based compensation expense of $20,663 was recognized as general and administrative expenses. During the six months ended June 30, 2014, total stock-based compensation expense of $19,355 was recognized as general and administrative expenses.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">There were 100,000 stock options vested and 100,000 stock options unvested as of June 30, 2015. As of June 30, 2015, the Company had $13,046 of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized by June 15, 2020.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company issues new shares when options are exercised.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 1, 2013, the Company engaged Vector to assist the Company with identifying subject matter experts in the medical device and biotechnology industries and to assist the Company with its ongoing research, development and eventual commercialization of its Regeneration Technology (collectively, the &#147;Services&#148;). In consideration of the Services, the Company will pay Vector a monthly consulting fee of $5,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Company&#146;s anticipated Section 510(k) submission of its proprietary SkinGun<sup>TM</sup> to the Food and Drug Administration, the Company has engaged StemCell System GmbH (&#147;StemCell Systems&#148;) to provide it with prototypes and related documents. Pursuant to this engagement the Company incurred expenses of $44,910 in the three months ended June 30, 2015.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 25, 2014, the Company entered into a Charitable Grant Agreement with the University of Pittsburgh (the &#147;University&#148;), pursuant to which the Company committed to provide a charitable donation to the University in the aggregate amount of $75,000 (the &#147;Grant&#148;). The Company will pay the Grant in eight quarterly installments of $9,375, with the first payment made on or before October 2014 and the final payment to be made on or before July 31, 2016. Dr. Gerlach, from whom the Company purchased the SkinGun<sup>TM</sup>, is a professor at the University. At June 30, 2015, $37,500 of the amount payable to the University was recorded as current liabilities and $9,375 was recorded as long-term liabilities in the accompanying consolidated balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See also &#147;Note 7. Related Party Transactions.&#148;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As compensation for their service on the Board, Dr. Kirkland and Mr. Sierchio will receive an annual retainer of $6,000, payable in equal yearly installments in arrears and prorated for any partial years of service.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For the three months ended June 30, 2015, directors&#146; and consulting fees payable to officers and directors of the Company were $3,000 (2014: $3,000). Legal fees paid or payable to one of the Company&#146;s directors in the three months ended June 30, 2015 were $28,125 (2014: $27,820). For the six months ended June 30, 2015, directors&#146; and consulting fees paid or payable to officers and directors of the Company were $6,000 (2014: $6,000). Legal fees paid or payable to one of the Company&#146;s directors in the six months ended June 30, 2015 were $67,105 (2014: $82,185). Amounts included in accounts payable and accrued expenses, and due to related parties, were $23,800 at June 30, 2015 and $36,080 as of December 31, 2014.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On July 1, 2015, the Company appointed Dr. Richard Simman to its Scientific Advisory Board and issued Dr. Simman an option to purchase 7,500 shares of the Company&#146;s common stock at a price of $1.34 per share, the closing price of the Company&#146;s common stock as quoted on the OTCQB on June 30, 2015. The option may be exercised on a &#147;cashless basis&#148; using the formula contained therein and, subject to Dr. Simman&#146;s continued service with the Company. The shares underlying the option vest on December 31, 2015.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Subsequent to the period ended June 30, 2015, the Company issued to Dr. Jorg Gerlach 196,812 shares of its common stock upon the cashless exercise of 240,000 vested shares included in the Series A Warrant issued to Dr. Gerlach pursuant to the asset purchase agreement entered into between the Company and Dr. Gerlach on July 12, 2013.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The interim consolidated financial statements included herein have been prepared by the Company, without audit, in accordance with the rules and regulations of the Securities and Exchange Commission (&#147;SEC&#148;) pursuant to Part 210 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) have been condensed or omitted pursuant to such SEC rules and regulations, although the Company believes that the disclosures included are adequate to make the information presented not misleading.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In management&#146;s opinion, the unaudited consolidated financial statements contained herein reflect all adjustments, consisting solely of normal recurring items, which are necessary for the fair presentation of the Company&#146;s financial position, results of operations, and cash flows on a basis consistent with that of the Company&#146;s prior audited consolidated financial statements. The Company has evaluated information about subsequent events that became available to us through the date the financial statements were issued. This information relates to events, transactions or changes in circumstances that would require us to adjust the amounts reported in the financial statements or to disclose information about those events, transactions or changes in circumstances. The results of operations for interim periods may not be indicative of results to be expected for the full fiscal year. Therefore, these financial statements should be read in conjunction with the Company&#146;s audited financial statements, including the notes thereto for the year ended December 31, 2014, which may be found under the Company&#146;s profile on EDGAR.</p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These consolidated financial statements have been prepared in accordance with US GAAP and include the accounts of the Company and its wholly owned subsidiary, RenovaCare Sciences. All significant intercompany transactions and balances have been eliminated. RenovaCare Sciences was incorporated under the laws of the State of Nevada on June 12, 2013.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board&#146;s Accounting Standards Codification.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the Financial Accounting Standards Board (&#147;FASB&#148;) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification (&#147;ASC&#148;) 605, Revenue Recognition. The new revenue recognition standard requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for interim and annual reporting periods beginning after December 15, 2017 and is to be applied retrospectively. The Company does not currently have any revenue. As such, ASU 2014-09 will not have any effect on the Company&#146;s results of operations and financial position. If the Company begins generating revenue prior to the effective date of ASU 2014-09, it will evaluate the effect that ASU 2014-09 will have on its results of operations and financial position.</p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results, as determined by future events, may differ from these estimates.</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents may at times exceed federally insured limits.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts for cash and cash equivalents and payables approximate fair value based on observable quoted prices for active markets &#150; Level 1 inputs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company intends to outsource its research and development efforts and expense related costs as incurred, including the cost of manufacturing product for testing, licensing fees and costs associated with planning and conducting clinical trials. The value ascribed to patents and other intellectual property acquired will be capitalized as it relates to particular research and development projects that may have alternative future uses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The intangible asset consists primarily of SkinGun<sup>TM</sup><sub> </sub>technology that the Company acquired during 2013 and is recorded at cost. At the time of acquisition the technology had not reached technological feasibility. The amount capitalized is subject to impairment testing until completion or abandonment. Upon successful completion, a determination will be made as to the then useful life of the intangible asset, generally determined by the period in which substantially all of the cash flows are expected to be generated, and begin amortization. The Company tests the intangible asset for impairment at least annually or more frequently if impairment indicators exist after performing a qualitative analysis. Management has multiple criteria that it considers when performing the qualitative analysis. The results of this review are then weighed and prioritized. If the totality of the relevant events and circumstances indicate that the intangible asset is not impaired, additional impairment tests are not necessary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company assessed the following qualitative factors that could affect any change in the fair value of the intangible asset: analysis of the technology&#146;s current phase, additional testing necessary to bring the technology to market, development of competing products, changes in projections caused by delays, changes in regulations, changes in the market for the technology and changes in cost projections to bring the technology to market. Based on a qualitative assessment, management concluded that a positive assertion can be made from the qualitative assessment that it is more likely than not that the intangible asset related to the SkinGun<sup>TM</sup> is not impaired. The Company did, however, determine that an intangible asset related to wound care technology, acquired during 2013, was impaired during the period ended June 30, 2015 and recorded an impairment loss (a component of research and development expenses) amounting to $10,000 which was equal to the amount capitalized.</p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company measures all stock-based compensation awards using a fair value method on the date of grant and recognizes such expense in its consolidated financial statements over the requisite service period. The Company uses the Black-Scholes pricing model to determine the fair value of stock-based compensation awards on the date of grant. The Black-Scholes pricing model requires management to make assumptions regarding option lives, expected volatility, and risk free interest rates.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company recognizes income taxes on an accrual basis based on tax positions taken, or expected to be taken, in tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#146;s financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. Should they occur, the Company&#146;s policy is to classify interest and penalties related to tax positions as interest expense. Since the Company&#146;s inception, no such interest or penalties have been incurred. The Company did not record an income tax provision during the periods presented due to net taxable losses.</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company presents both basic and diluted earnings per share (&#147;EPS&#148;) amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. Potentially dilutive shares of common stock consisted of warrants to purchase shares of common stock (9,210,000 shares as of June 30, 2015 and 8,200,000 at December 31, 2014) and options to purchase shares of common stock (200,000 shares as of June 30, 2015 and 185,000 as of December 31, 2014). During the periods presented, potentially dilutive shares of common stock were not included in the computation of dilutive loss per share as to do so would be anti-dilutive.</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A related party is generally defined as (i) any person who holds 10% or more of the Company&#146;s securities and their immediate families; (ii) the Company&#146;s management; (iii) someone who directly or indirectly controls, is controlled by or is under common control with the Company; or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. See &#147;Note 7. Related Party Transactions,&#148; for further discussion.</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom">&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom">&#160;</td> <td>&#160;</td></tr> <tr> <td style="vertical-align: bottom">&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>Average</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom">&#160;</td> <td>&#160;</td></tr> <tr> <td style="vertical-align: bottom">&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>Remaining</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>Aggregate</b></font></td> <td>&#160;</td></tr> <tr> <td style="vertical-align: bottom">&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>Options</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>Average</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>Contractual</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt"><b>Intrinsic</b></font></td> <td>&#160;</td></tr> <tr> <td style="vertical-align: bottom">&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Outstanding</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Exercise Price</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Life (Years)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Value</b></font></td> <td>&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Balance January 1, 2015</font></td> <td style="width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">185,000</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">0.83</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">9.12</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">94,150</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Options granted</font></td> <td style="text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">15,000</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.34</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">10.00</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="vertical-align: bottom"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Balance June 30, 2015</font></td> <td style="text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">200,000</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">0.80</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">8.87</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">94,150</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Exercisable at June 30, 2015</font></td> <td style="text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">100,000</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="vertical-align: bottom"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">0.81</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">8.71</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="vertical-align: bottom"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">53,250</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="background-color: white"> <td nowrap="nowrap" style="vertical-align: bottom; width: 60%"><b>&#160;</b></td> <td nowrap="nowrap" style="vertical-align: bottom; width: 20%; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td> <td style="vertical-align: top; width: 20%; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2014</b></font></td></tr> <tr style="background-color: rgb(204,238,255)"> <td nowrap="nowrap" style="vertical-align: bottom"><font style="font-size: 10pt">Weighted average risk-free interest rate</font></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">1.49 &#150; 1.71%</font></td> <td style="vertical-align: top; text-align: center"><font style="font-size: 10pt">1.43 &#150; 1.62%</font></td></tr> <tr style="background-color: White"> <td nowrap="nowrap" style="vertical-align: bottom"><font style="font-size: 10pt">Expected life in years</font></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">5.50</font></td> <td style="vertical-align: top; text-align: center"><font style="font-size: 10pt">4.50 &#150; 5.50</font></td></tr> <tr style="background-color: rgb(204,238,255)"> <td nowrap="nowrap" style="vertical-align: bottom"><font style="font-size: 10pt">Weighted Avg. Expected Volatility</font></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">94.4%</font></td> <td style="vertical-align: top; text-align: center"><font style="font-size: 10pt">99.5 &#150; 105.3%</font></td></tr> <tr style="background-color: White"> <td nowrap="nowrap" style="vertical-align: bottom"><font style="font-size: 10pt">Expected dividend yield</font></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">$0</font></td> <td style="vertical-align: top; text-align: center"><font style="font-size: 10pt">$0</font></td></tr> </table> P10Y P5Y6M P4Y6M P5Y6M 0.0149 0.0143 0.0171 0.0162 0.944 0.995 1.053 0 0 15000 9375 23800 36080 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On June 5, 2015, the Company entered into subscription agreements with five investors for the purchase and sale of an aggregate of 1,010,000 units of equity securities (the &#147;Units&#148;) at a price of $1.00 per Unit for total gross proceeds of $1,010,000. Each Unit consists of one share of common stock and one Series D Stock Purchase Warrant (the &#147;Series D Warrants&#148;) allowing the holder to purchase one share of the Company&#146;s common stock at a price of $1.10 per share for a period of five years; the Series D Warrants contain a provision allowing the holder to exercise the Series D Warrant on a cashless basis as further set forth therein.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The relative fair value of the common stock was estimated to be approximately $590,000 and the relative fair value of the Series D Warrants was estimated to be $420,000 as determined based on the relative fair value allocation of the proceeds received.&#160;&#160;The Series D Warrants were valued using the Black-Scholes option pricing model based on the following assumptions: risk free interest rate of 1.75%, contractual life of five years, expected volatility of 88.0% and a dividend yield of 0%.</font></p> EX-101.SCH 6 rcar-20150630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Organization, Nature and Continuance of Operations link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Intangible Assets - Intellectual Property link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Common Stock Options link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Common Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Organization Nature and Continuance of Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Intangible Assets - Intellectual Property (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Common Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Common Stock Options (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Common Stock Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 rcar-20150630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 rcar-20150630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 rcar-20150630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Officer and directors [Member] Related Party [Axis] Management Fee [Member] Title of Individual [Axis] Non Officer Director [Member] Directors [Member] Legal Fee [Member] Advisory Fees Common Stock Equity Components [Axis] Additional Paid-In Capital Accumulated deficit Cumulative since Feb 20, 2013 (Inception of Development Stage) Accumulated deficit Accumulated other comprehensive (loss) Total Liabilities [Member] Liability Class [Axis] Mining Properties [Member] Property, Plant and Equipment, Type [Axis] Asset Retirement Obligation Level 1 [Member] Asset Retirement Obligation Level 2 [Member] Asset Retirement Obligation Level 3 [Member] Other current assets [Member] Accounts payable [Member] Asset retirement obligation [Member] Option Granted [Member] Plan Name [Axis] Option Cancelled [Member] Option Exercised [Member] Assets [Member] Warrant Class of Warrant or Right [Axis] Equity Option [Member] Employee Stock Ownership Plan (ESOP) Name [Axis] Type of Deferred Compensation [Axis] Employees and Directors Minimum Range [Axis] Maximum Two Directors Employee $0.50 to $1.00 [Member] $1.01 to $1.50 [Member] Officers and Directors [Member] Consulting fees [Member] Officer [Member] Dr Gerlach [Member] Finite-Lived Intangible Assets by Major Class [Axis] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Consolidated Balance Sheets ASSETS Current assets Cash and cash equivalents Prepaid expenses Total current assets Intangible Assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable and accrued expense Accounts payable and accrued expenses - related parties Contract and contribution payable Total current liabilities Long term liabilities Contract and contribution payable, less current portion Total liabilities STOCKHOLDERS' EQUITY Preferred stock: $0.0001 par value: Authorized: 10,000,000 shares, Issued and outstanding: nil Common stock: $0.00001 par value: Authorized: 500,000,000 shares, Issued and outstanding: 67,585,122 and 66,575,122 shares Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Consolidated Balance Sheets Parenthetical Preferred stock, par value Preferred stock, Authorized Preferred stock, shares Issued Preferred stock, shares outstanding Common stock, par value Common stock, Authorized Common stock, shares Issued Common stock, shares outstanding Consolidated Statements Of Operations Revenue Expenses Research and development expenses General and administrative expenses Total operating expenses Net loss Earnings per share - basic and diluted Loss per common share Weighted average shares outstanding Consolidated Statements Of Cash Flows Cash flows from operating activities Adjustments to reconcile net loss to net cash flows from operating activities: Impairment loss Stock based compensation expense Stock based consulting expense Changes in operating assets and liabilities: Receivables Prepaid expenses Accounts payable and accrued expenses Accounts payable and accrued expenses - related party Contract and contributions payable Net cash flows from operating activities Cash flows from financing activities: Proceeds from sale of common stock plus warrants Change in cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Notes to Financial Statements Note 1. Organization, Nature and Continuance of Operations Note 2. Significant Accounting Policies Note 3. Intangible Assets - Intellectual Property Note 4. Common Stock Options Note 5. Common Stock Note 6. Commitments Note 7. Related Party Transactions Note 8. Subsequent Events Significant Accounting Policies Policies Basis of Presentation and Principles of Accounting Principles of Consolidation Applicable Accounting Guidance Accounting Estimates Cash and Cash Equivalents Fair Value of Financial Instruments Research and Development Costs Intangible Assets Stock Options Income Taxes Earnings (Loss) Per Share Related Party Transactions Common Stock Options Tables Stock Option Activity Assumption of stock option activity Organization Nature And Continuance Of Operations Details Narrative Accumulated deficit Significant Accounting Policies Details Narrative Common stock consisted of warrants to purchase shares Options to purchase shares of common stock Statement [Table] Statement [Line Items] Impairment loss Intangible assets Other current liabilities Other long term liabilities Consulting expense associated with the Series A Warrant amounted Research and development costs associated with the Series A Warrant amounted Common Stock Options Details Options Outstanding Options outstanding - beginning balance Options granted Options oustanding - ending balance Options exercisable Weighted average exercise price Options outstanding - beginning balance Options granted Options outstanding - ending balance Options exercisable Weighted average remaining contracted term Warrants outstanding - beginning balance Options granted Warrants outstanding - ending balance Warrants exercisable Aggregate intrinsic value Options outstanding - beginning balance Options granted Options outstanding - ending balance Options exercisable Weighted average risk-free interest rate Expected life in years Weighted Avg. Expected Volatility Expected dividend yield Common Stock Options Details Narrative Shares available for grant Stock options granted Stock-based compensation administrative expense Stock options vested Stock options unvested Unrecognized compensation cost Commitments Details Narrative Incurred expenses Other long term liabilities Fees paid or due to related party Accounts payable - related parties Accounting Standards Codification Policy [Text Block] Custom Element Custom Element Depreciation and Impairment Losses Asset retirement obligation level 1. Asset retirement obligation level 2. Asset retirement obligation level 3. Asset retirement obligation. Common stock options. Consulting expense associated with the Series A Warrant amounted. Contract and contribution payable. Contract and contribution payable, less current portion. Custom Element Decrease increase in contract and contribution payable. Custom Element. Custom Element. Custom Element. Option cancelled. Option exercised. Option granted. Related Party Transactions Policy [Text Block] Research and development costs associated with the Series A Warrant amounted. warrants exercisable Shares available. Custom Element Stock based consulting expense. Stock options policy. Stock options unvested. Total liabilities. Unrecognized compensation cost. Weighted average remaining contracted term Proceeds from sale of common stock plus warrants. Common Stock. Assumption stock option activity. Stock options granted. Other long term liabilities. Assets, Current Assets Liabilities, Current Liabilities Retained Earnings (Accumulated Deficit) Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities Goodwill and Intangible Assets, Policy [Policy Text Block] Cumulative Earnings (Deficit) Impairment of Intangible Assets, Finite-lived Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable OtherLongTermLiabilities EX-101.PRE 10 rcar-20150630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`+![#4=W8;7KCP$``*@0```3````6T-O;G1E;G1?5'EP97-= M+GAM;,U8RT[#,!#\E2I7U+@.4!YJ>Z%W!/B\@HD0&#AST0:T\39HS@.?-<*U*KHE5UJ,N2 MYU#H?"U#2NH#-5P$/!DLF/5/3(829"M(`^R?-(TX.0^A,Q98X2H`+T7J_$Z` MZ^+?(Q_,^39.`NJ,8VHF_*>,R-LVH MY;>,./_C6EJ;6$LQMVS#6P1U;VV*8RH95UVMVFB[>M-Z=+%V]#?[KOQ-:`_';&OS?M/ M36]`1YJA1Y,X24>&1,PU'2'4%[L4````K`@``"P```%]R96QS+RYR96QSK9++;L)` M#$5_)9I]<4HE%A%AQ88=0OR`.^,\E,QXY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL M#C2B]AQ2U\=43'X,JQW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6: ME((C-Z."N[_8_`)02P,$%`````@`L'L-1Q^Q">Y)`0``,@\``!H```!X;"]? MQTZ:WS;C3YY'WKC M\^E](=H0QEQ*7[8X:+^Q(YIIM;9NT&%Z=(T<=7G7#4J5IIETRSGB-!*AZD6(*V\:`M2]`N'K1C"=K'@_8L05D\*&,).L2##BQ!QWC0D27H%`\Z ML01!2LB8\B116/-H#037P.,U$&`#C]A`D`T\9@.!-O"H#03;P.,V$'`#C]Q` MT`T\=@.!-_#HK0B]%8_>BM!;,9VUJ<,VC]Z*T%OQZ*T6>OM6.ZR>@^M,X]>N M^3:<+%K@[<.CQ_53YJEDPT+K,.V$F#1(6]`V5252EF8""9J*9.S9.-?6PK$S^U)1?OTN"60IM+#RL+SD?/[N MSM]W%V>BW6`\MZ8$BQ(<>RB4=F-RGGLKQ'+L^TZLH.#NA"":=A?&%AQI:9>^ M62RD@*D150$:_=%@\,6'!P2=0WY<=DF]8%)7"04]&M[)VSP5QLB*>J8Z,5UTO(^]C7F\]:W()U-=/A MZ&1`3R?!L[_-#3R7>CGGTKI@LL;Q&@0:^]2F-7ZT2[D1==/=;4;G6;;V-K4J'-OAE[+U;`:";^)VS,?O8OBW/@M%I@R!K M&^EWS((GV;9XUYY,H@*7+.;7TS"+I^Q[>!7.HIBE%W&$3WZP9![? M'!H3A>G%SIC$+KF6CPW9SVS&L;+0:!$9$F,W_U0NM23]J>,L%,)4-7+)YH8^ M>KHE=L9<:J2O1MXI8*%S-&SLF'1&4(J:7^W1P!2%T2Q%(^Y94M9'W)V\#]P+ MD%CW>7>"&U!T4^2LGLD-RRS7CHO]]=+JSL'OJAZ;>+TWZ9LR#<_^F3([RCCI MYCZ]V\#7_:L^<+*OAS=P^.T`-E-`+M4>.F^&L.$'8F;O340/RJTE(=>P^VS[ MIZ1)\>KZ[-^#+VX]?_MO'?P!4$L#!!0````(`+![#4>BO(XS/P$``&D#```1 M````9&]C4')O<',O8V]R92YX;6S-DTU/PS`,AO\*ZKU+NVD(JJX'0)R8A,00 MB%N6>%M8\Z'$4]=_3^9U+0,NNR'U4-=^'[^NDU*X0E@/S]XZ\*@@7.UU;4(A MW"S9(+J"L2`VH'D8Q0H3DROK-<<8^C5S7&SY&M@XRZZ9!N22(V<'8.IZ8E*5 M4A3"`T?K.[P4/=[M?$TP*1C4H,%@8/DH9TGU:K;&-J9D@[XJH^.:!YQ;J58* MY%T[E/U.QC'&3?GK[^Z8$R+.DJ]T'U54W3C)H)U<6!<_8^?WJA?Y,J M$Y`;`5$55(&M@UERZOPVN7]8/";5.,NG:7:3YI-%/BW&M_'Y.$QVYF\PK+LA M_JWCDT':+BJLX<+=DD;2N;&U]>TS]B,YN5?4%4$L#!!0````(`+![#4>97)PC$`8` M`)PG```3````>&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O& M-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5' MY^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\,`*I4Q>M5II`,,X M?+&A`T%116F]? M(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D M3EJ(X53"Q,!J9S]6:\?1TDB`@LE]E`6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS* MVG0T;1K@X_%X.+;+THMP'`3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3 M]WW?ZYMHG`J-6T_3:W?=TXZ)QJW0>`V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H M0D;CZWH2%;7E0-,@`%AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9I MTAF6-$9RG9`%#@`WQ-%,4'RO0;:*X,*2TER0UL\IM5`:")K(@?5'@B'%W*_] M]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+`GQ^R-;88C'(CN]WV6'WV3T=N M(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0'`*D"3&6H8;XM,:L$>`3 M?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0 MKH)[`?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO`J MQ`GH9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3- M"S-#MW)+ZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@: M0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\ MEAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE`T%&ULK"0L1K=@N-?Q+!3@9&`MH`># MKU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@3 M9ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$! M=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_ M6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ`$:MBOKJO3_DEG#NT>_&!()O\UMND M]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC? MAT6:&C/5BZPYC0IO0=5`Y3_;U`UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2. MX>V+OP%02P,$%`````@`L'L-1YW0N@1;`@``>`L```T```!X;"]S='EL97,N M>&ULS59=:]LP%/TK0AFCA1';Z9JVJVT8A17"A5/G%\ZIT@1FJQJ+$ M7*_D0C*D]%067E5*C++*!#'J37Q_ZC%$.(Q#7K,94Q5(10^_UI&-?/SN9[>J` M?GHP_1[^88*;`Q/\BWU`?6NHO?8.XC`7O+^*"71`'%8O8(FH]@^,>RJHD$#I MN]8:+,(1P\[C`5&22&+`'#%"5PZ>&,"61^O'"!?2YG89AGG&?I])%DD$_?9Y M?;JD9[>#V1ZA='M[&HC#$BF%)9_I"6CM^:K4F^."8R?2^NWQ+B1:!9/KC0`[ MZ+R)D!F67>8`KJ$XI#A7.D"28F%&)4HC72@EF#8R@@K!$364ZXC6T+0IIO3) MO(R_\BWN)@?.Q]RQ#X%1L3;U0;1F7P;V4+U--L>]23LYBA9=`1Z.RI*NO ME!2<82?603/1SO;1!SOHXQ"M6<%"2/*B_4TAI!K`$H(EEHJDF\@?BJQ9@N7,?A@/EW1UL__*[-L)!S+? MMVJ.D'""PS&]\VRE3<]7VMO4U$FDW9ZKM*N[_U3FM3UKHS%NM<4.!4E-J")\ M+0&9'YE'(YMN=:R^)6K.K.F[H5U5*-&_P5M9-%F&SM[T9^ M,.V\YAU%!'O[!\Y(S>ZL@OY?._X+4$L#!!0````(`+![#4>F9)4>_0(``-<( M```/````>&PO=V]R:V)O;VLN>&ULE95;4^(P%(#_2J9/[LSNEE1`9:PS"'5E M1H&QC/LN&IS>U+,',3U5RZ=H62A?,NJ)>AFJQ@(P/55857-HP:K6ZH>:"65#2 MK*`TP0O-?(5F2LU9;E:MMWJ5)-,Y7P#FZW`_'YI"$C.%ZP2 M=N86NYTW#FC4CJ+NAN&[W0-?&PST%81E%A[YC,WCH!405EEU!<)R/626_]*J M*D$N'2L@"]#&IGZ[=<\")!3P[-?M2F:EUM=*P[.2EHDTTTJ(>I1OJ`>Y&/@=.8^M\G802979#)-[A"HC4#M@T"# M?GJ-0!T$ZNR#)GK))#S74?U.QLQ6FM=!'S@/``>ZBT#=?5`*2PGN=C)W:/TL M4Y4?OB13)2`#;A#H!(%.]D$CYY]<>EU(WQCG!OGACMYR(7AF*QSL4P0Z;8B1 M*@IW>U.KL@LW`HT^0Z///AZ-=6MAWUK-X\!Z=_%D=$?3!D_O_"O&7R[!.PF;9#SPQ.D;8S"=M(F/1M" M3X[<`R*X^89!V$[ZB9[[=E88A?VDAPI*3S`*&TH/592>8A1VE'Y14G(TY):! MV`T5]I5^(NP>B5#\VF&'HW<!T1@6C.?M/`&HYU'N$'N M]Z](3<8HK'IT_))V7C.-2[8@>>[SL*FG<8DL\\G9?3;WK-WQ\?;E6Y>PX\!G M59=`*R$&KFXB;Q2K<\^&O$W'%_\`4$L#!!0````(`+![#4>(_MXW;@(``,`( M```8````>&PO=V]R:W-H965T&ULC9;;CILP$(9?!?$`"S:G M)")(2:JJO:BTVHOVVDF<@!8PM9VP??OZ`*QQK<(-8//_\XW!PY#WA+ZS$F/N M?31UR_9^R7FW"P)V*7&#V`OI<"ONW`AM$!=#>@]81S&Z*E-3!S`,TZ!!5>L7 MN9I[I45.'KRN6OQ*/?9H&D3_''%-^KT/_''BK;J77$X$11Y,OFO5X)95I/4H MONW]`]B=0"HE2O&SPCTSKCV9_)F0=SGX?MW[HLQ^E>U7)'^&3%\(O6OZLI+D6WH>U=\0X^:OY'^&Q[6D,B`%U(S M=?0N#\9),UI\KT$?^ERUZMSK.S$8;&X#'`QP,L#TOX9H,$23`<1JI3HSM:XO MB*,BIZ3W6(?DVP8[(:#O_[.C`:!@-IG?52)EW M(8^6ZWXQS4[-^@!5P_F4%WF'[O@'HO>J9=Z9<-&V5(^Y$<*Q2"-\$>F4XG=B M&M3XQN5E)O/4#58/..G&_X7IIZ7X"U!+`P04````"`"P>PU')"N0:4$#```O M#0``&````'AL+W=O6L/ M6G?11U76[3(^=-WQ,4G:S4%7>?M@CKJV_^Q,4^6='3;[I#TV.M\.0569$(1$ M4N5%':\6P[7G9K4PIZXL:OW<1.VIJO+F[UJ7YKR,<7RY\%+L#UU_(5DMDFO< MMJATW1:FCAJ]6\9/^#$CI)<,BE^%/K?@/.KA7XUYZP<_MLL8]0RZU)NN3Y'; MP[O.=%GVF>S,?Z:DGW/V@?#\DOW;4*[%?\U;G9GR=['M#I86Q=%6[_)3V;V8 M\W<]U<#[A!M3ML-OM#FUG:DN(7%4Y1_CL:B'XWG\1Z$I+!Q`I@!R#<#LOP%T M"J!>0#*2#75]S;M\M6C,.6J/>7^W\:.5-WT2FSEJAVS-N%RVLM9>?5\1N4C> M^SR3A`R2M2,)*3)'H:Z2Q,X?A"`7B''X1&!\>C^>7N+9&$]!/$4NHAR+&"7U M(,%8$"YX2)=!G5`4I3/*81X.@SC8G8:/.`Q,0U**94B5095D;`8*]U`X1"%! M%.ZL3(J5"NHRJ!,IXDSCH`X-(@C(`XGBK,@C2,3CNPFC?1H)*0)3K.6 M/MTA$PR2N<@^29&H(FQ--A(Q#&QT!8Z-9,C#.ZA"7BU M/>9[_3-O]D7=1J^FLV_)PROMSIA.VVSHP19ZL%\OUT&I=UU_*OL5&-_GQT%G MCI?/D^LWTNH?4$L#!!0````(`+![#4&PO=V]R M:W-H965T&ULC97+CILP%(9?!;%O;"X&$A&D&:JJ750:S:)= M.XD3T`"FMA.F;U]?(&.0R30+[&/^_YSO.,C.!\K>>$6(\-[;IN-[OQ*BWP'` MCQ5I,=_0GG3RS9FR%@L9L@O@/2/XI$UM`T(($]#BNO.+7*^]L"*G5]'4'7EA M'K^V+69_GTE#A[T?^-/":WVIA%H`10[NOE/=DH[7M/,8.>_]IV!7!E!)M.)7 M309NS3T%?Z#T304_3GL?*@;2D*-0*;`<;J0D3:,RRD$AYIP_73.UZYH.UD\;T6OYNQ M[O0XF#,]5O]VL)-RII+( MS![7V9C9+MD9EZNW`L$41)JR;,M"5V*!&YJWD'7D/&G(6:IJJ@N;6,(&@_70)WF_BXA]02P,$%``` M``@`L'L-1WHW]L_6`@``DPH``!@```!X;"]W;W)KUE2J MQ_80B%/+Z*X3U56``"!!3[KX-\[?]<./ MW=('N@96L:W4(:BZ?+`UJRH=267^VP>]Y=1"^_X:_5MG5Y7_1@5;\^I/N9-' M52WPO1W;TW,E?_'+=]9[P#K@EE>B^_2V9R%Y?97X7DT_S;5LNNO%?$-`+W,+ M4"]`@V#(XQ:$O2"\":(O!5$OB![-@'L!GF0(C/=NYS94TCQK^<43)ZK["2X4 MWNH@*K(GNFBM>2%J[X1:_N!&N;(-!9P]T@Q4R0V3+#:YFAV:O0UJ/[^NBJCXP^LO7A?3V>Y,>V/KJO M)Y/\Q-;C\1;%YDT8I#'M`%#HI-8V13``P$5M;`I"2)`S6#$?;-98/#$6V\;( M.(M1K&*[&())BEW8VL8024B"7-C&QD(5"SBQPL9P2&+PP$M/)MX2VUOL]);8 M14.O[H2_ MA<^S$SVPG[0]E(WPWKA4'BNVEOHVU-S,SF0?) M3]<1<)A#\_]02P,$%`````@`L'L-1]??0O@#`P``>0L``!@```!X;"]W;W)K MQ=_8&-62:1-JJH]5%KMH3VS MB9.@!9QB9[/]][6!D,'R*J@Y!&S>S'MCX\QD=C3H]) MHK='61?Z09UD8Y_L55L7Q@[;0Z)/K2QV75!=)00AGM1%V<2K13?WW*X6ZFRJ MLI'/;:3/=5VT?]>R4I=EC./KQ$MY.!HWD:P6R1BW*VO9Z%(U42OWR_@)/VX( M4R6>8_0](;IPN$ M]]?LW[IRK?S70LN-JGZ7.W.T:E$<[>2^.%?F15V^RZ$&YA)N5:6[_VA[UD;5 MUY`XJHN/_EHVW?72/\GR(2P<0(8`,@:,/.$`.@306T#:5=HKZ^KZ6IABM6C5 M)=*GPNTV?K3PUB6QF2/=96O[Y;*5:3O[OLK((GEW>08(Z2!K",$C(K')@PPD MGH83$!XDV$`$G\%`KPS]\(G"&NC]^/0:G_;Q*>074XE97T0/:3K(EU1@3+(0 M;C/!<80S-$,/\^IAL)[T?CSWZN$PGDUULKX>#G1B9'_W63*/)8,L/+AJ&6`A MB',:7#.(PCEE[+X6X6D14$L6JG@C)BR,TAD;DWL;DT,:<3\>(T^G\Y5;ACPH M=,`,[Q#F<_8&8Y\('EJ*@[LS8`8B@@7_1-`41S'*9B@BOB)XR@4*OI4#IAD6 MV$<-[\L4A7)@6Y_+H;X<:!H"A^500$13GLW9"=]<,'070<)$$]NPYS%C!Q4:6M>\,^X%1IVNC.W;;JW]02P,$%`````@`L'L-1Q2Q$':C`0`` MK0,``!@```!X;"]W;W)KC=C%2U<7,VH$+6+6YC&U"^_;U#U!25>H&VY?S'1__Y2/J%]," M6/*J9&>.M+6V/S!FRA84-S?80^?^U*@5MVZH&V9Z#;P*D)(L2Y(?3''1T2(/ MM2==Y#A8*3IXTL0,2G']=@*)XY&F="X\BZ:UOL"*G"U<)11T1F!'--1'>I<> M3ENO"(*_`D:SZA.?_8SXX@>/U9$F/@)(**UWX*ZYP#U(Z8W^[-+#TZNO8ES)B:X MZ;AZ%]2XZJ6XW>?LXGTF221.:TFZ*)@S_W*&C%[CV0K/OL>(;+6?"G03KHTA)0Z=C=NY5)>;>9>%\_B0%WG/ M&_C#=2,Z0\YHW:F&(Z@1+;@,RPU'6"A2WZ,!``"M`P``&````'AL+W=O;0_@R(N2VIYH[]QP9,S6/2AN[W``[?^T M:!1W/C0=LX,!WD1(299GV2>FN-"T*F/NT50ECDX*#8^&V%$I;OZ=0>)THCNZ M))Y$U[N08%7)5JX1"K05J(F!]D3O=\=S$111\%O`9#=S$GJ_(#Z'X&=SHEEH M`234+CAP/USA`:0,1K[PW]GSM60`M_/%_7M_^PBT\H/PC&M?[9C-*&FCY M*-T33C]@7L(A&-8H;?R2>K0.U8)0HOA+&H6.XY3^%-F,O0_D,Y"OP)<(L%0H MMOF-.UZ5!B=B!Q[.;G?TJZ_[DEV#SRQ)Q'DKV:T* MYLW?K9#36SS?X/G'^'[!]ZG!_;;![&.^6/@B\<66+VX7F"3G&\GA30FVV4\% MIHO7QI(:1^W2=J[9]6;>Y_$\7N55.?`.?G'3"6W)!9T_U7@$+:(#WT-V=Z"D M]V]G#22T+DP_^[E)URD%#H?E<:POM/H/4$L#!!0````(`+![#4?`&PO=V]R:W-H965T&ULA9/;;IPP$(9?Q?(# MQ"R[FZ0K%BF;*FHO*D6Y:*^],(`5VT-LLZ1O7Q^`L%6DW&#/\'__C$_%B.;5 M=@".O"NI[9%VSO4'QFS5@>+V!GO0_D^#1G'G0],RVQO@=8249'F6W3+%A:9E M$7//IBQP<%)H>#;$#DIQ\_<$$L0>;S2BIH>&#="\X_H!I"?M@6*&T\4NJP3I4,T*) MXN]I%#J.8_JSSR;L%D8'(GM>3B[S<'+33#QSL1& M-Y-6[QNU/GLIO]T6[!)\)DDB3FO)9E$P;_YIA9Q>X_D*S[_&MS.^30UNUPUF M7_.[F=\E?K?F[ZX7F"2G*\G]?R78:C\5F#9>&TLJ'+1+V[EDEYOYD,?S^)"7 M1<];^,5-*[0E9W3^5.,1-(@.?`_9S9Z2SK^=)9#0N#"]\W.3KE,*'/;SXUA> M:/D/4$L#!!0````(`+![#4?V!YVTHP$``*\#```8````>&PO=V]R:W-H965T M&ULA5/;3N,P$/T5RQ^`W;2P4*61*"O$/JR$>-A]=I/)1=B> M8#L-^_?XDH1TA<1+/#,YY\P97_(1S:MM`1QY5U+;`VV=Z_>,V;(%)>P5]J#] MGQJ-$LZGIF&V-R"J2%*299S?,"4Z38L\UIY-D>/@9*?AV1`[*"7,OR-('`]T M0^?"2]>T+A18D;.%5W4*M.U0$P/U@=YO]L==0$3`GPY&NXI)\'Y"?`W)K^I` M>;``$DH7%(1?SO``4@8AW_AMTOQL&8CK>%9_C--Z]R=AX0'EWZYRK3?+*:F@ M%H-T+S@^P33"=1`L4=KX)>5@':J90HD2[VGM=%S']&?+)]K7A&PB9`OA-A)8 M:A1M_A1.%+G!D=A>A+/;[#WA,D,0XKB&; M!<&\^)<=,GI)SU;T['OZ=J9OD\'MVB#_GK^;^;O$WZW=]'`;V&:3EMR0N?/-1Y"C>C`F^!7 MUY2T_O4LB83:A?"'CTVZ4"EQV,_/8WFCQ0=02P,$%`````@`L'L-1RLP&ULA9/;;IPP$(9? MQ?(#Q"R0'E8L4C91U5Y4BG+17GMA."BVA]AF2=^^/@"!*%)NL#W\WS\S/A03 MZF?3`5CR*H4R)]I9.QP9,U4'DIL;'$"Y/PUJR:U;ZI:900.O`R0%2Y/D"Y.\ M5[0L0NQ1EP6.5O0*'C4QHY1<_SN#P.E$#W0)//5M9WV`E05;N;J7H$R/BFAH M3O3N<#SG7A$$?WJ8S&9.?.T7Q&>_^%6?:.)+``&5]0[<#5>X!R&\D4O\,GN^ MI?3@=KZX_PC=NNHOW,`]BK]];3M7;$))#0T?A7W"Z2?,+=QZPPJ%"5]2C<:B M7!!*)'^-8Z_".,4_63)C'P/I#*0K\"T`+"8*93YPR\M"XT3,P/W9'8Y.KKV) M:-9$Y+S3K`KFW#],D=(]GF[P]',\6_`L5IAM M\._)YWR^\'GD\UV'V;[#J#GO-?F[)&RSI1)T&VZ.(16.RL8=7:/KY;Q+PY&\ MRS[K0D!C_?2KF^MXH^+"XK"\ MC_61EO\!4$L#!!0````(`+![#4=E=\\UI0$``+`#```9````>&PO=V]R:W-H M965TH/MX?_^F?$A&U"_F`;`DCG0JVX=4M=,]-IX&6`E&1IDEPSQ45+\RS$GG2>86^E:.%)$],KQ?7[ M"20.1[JA4^!9U(WU`99G;.9*H:`U`ENBH3K2V\WAM/.*(/@G8#"+.?&UGQ%? M_.)/>:2)+P$D%-8[<#=OH^9G2@\OYY/X0NG75G[F!.Y3_16D; M5VQ"20D5[Z5]QN$1QA;VWK!`:<*7%+VQJ":$$L7?XBC:,`[QSS89L>^!=`32 M&?@5`!83A3+ON>5YIG$@IN/^[#8')]?>Q#D3$]QT[-X5:ESTDF^2?<8NWFC4 M1.2TTLP*YMR_39'2-9XN\/1G?#OAVUCA=H'_3G[F=Q._B_QNU>'UNL.H.:TU M-U^2L,66*M!UN#F&%-BW-N[H')TOYVT:CN13GF<=K^$OU[5H#3FC=0<;3J%" MM."*2*[VE#3N^&ULA5/; M;IPP$/T5RQ\0`[MIDQ6+E$U5M0^5HCRTSUX8P(KMH;99TK^O+PN!*%)>\,QP MSIDSOI03FA?;`SCRJJ2V1]H[-QP8LW4/BML;'$#[/RT:Q9U/3&PO M=V]R:W-H965T:]H6838HRX+'*WH%3QJ M8D8IN?YW!H'3B:9T"3SU;6=]@)4%6[FZEZ!,CXIH:$[T+CV>#UX1!']ZF,QF M3GSM%\1GO_A5GVCB2P`!E?4.W`U7N`L,*A0E?4HW&HEP02B1_C6.OPCC%/WDR M8Q\#V0QD*_`M`"PF"F4^<,O+0N-$S,#]V:5')]?>Q#D3$]QT[-X5:EST6J9I M6K"K-YHU$3GO-*N".?9.7Q1_K(RW_`U!+`P04```` M"`"P>PU'&,Y&5CT"```:"```&0```'AL+W=OBLHBFN%/3DDXTK`LX.>_#9[0[H%Q+C.)W0P8Q&PD?L2`OC/YI3K)6V<9A M<")G?*7RC0T_R'T/)L.*46%^@^HJ)&O'D#!H\8=]-IUY#O9-CNYA_H#D'I!, M`9O8)&Y!)LUO6.*RX&P(1(]U\=!.R;DV4R%0,V"Z.O_@,@"AU M/[=H=G:WA%_,%26"BET[:8_N:76Z!I\3<_9_RLNBQQ?R"_-+TXG@R*2Z07G4C6CS?Q]'>@_`]02P,$%`````@` ML'L-1U(]QJ^R`0``%@0``!D```!X;"]W;W)K&UL MC53;;J,P$/T5RQ]0$TBZW8@@-:VJ[L-*51^ZSPX,8-47:IO0_?OZ`A2J2.T+ M]HS/.7-&8Y,/2K^:%L"B=\&E.>#6VFY/B"E;$-12JMYQ)>-+(]$)0_?\(7`T'O,%3XIDUK?4)4N1D MYE5,@#1,2:2A/N#;S?ZX\X@`>&$PF,4>>>\GI5Y]\*X M`\Z]D"O\-FI^EO3$Y7Y2?PC=.O:,1$RG&%F1'$J5\LD>(U/5W0 MT^_IV43/HL-LY?#W]P+;26`;!;9+@6VR;C%BCFO,#YK3*N6C=(YT##K7UVU]NK^.]C8%5W?0*YU]!\0%02P,$%`````@`L'L-1TQH M=DF-`0``/`,``!D```!X;"]W;W)K&ULA9--;MLP M$(6O0O``H2S;,6K(`NH40;(($&31KFEK9!$A.2I)6^GM.R0EU0X"5`MQAIKW MS>./J@'=N^\``OLPVOH=[T+HMT+X8P=&^COLP=*7%IV1@5)W$KYW()LD,EJ4 M17$OC%26UU6:>W5UA>>@E857Q_S9&.G^[$'CL.,+/DV\J5,7XH2H*S'K&F7` M>H66.6AW_/MBNU_&BE3P4\'@KV(6O1\0WV/RW.QX$2V`AF.(!$G#!1Y`ZPBB MQK]'YK^647@=3_3'M%IR?Y`>'E#_4DWHR&S!60.M/.OPAL,3C$M81^`1M4]O M=CS[@&:2<&;D1QZ53>.0OVR*4?:UH!P%Y2PHL_'<*-G\(8.L*X<#\[V,9[?8 M4KF+$"(SGV@NKYZ,>IJ]U(O5JA*7"!IKLF1_6[.>:P3QOVQ23DV6N4EY`[C_ M/V`Y`589L+P"K#:W)C?99"ZQJ>0;W3QZ/O415SO3RQ.\2'=2UK,#!MKDM",M M8@"B%7=KSCJZRG.BH0TQW%#L\NGF)&`_W=7YAZG_`E!+`P04````"`"P>PU' M3N=84;D!``!&!```&0```'AL+W=O9)Z)LV9-"R\2J3/G5/[>`Q/]+DJB,?':G&IM$SC/\,0K M&PZM:D2+)%2[Z"'9%JE%.,!;`[T*YLAZ/PCQ;H/G@^:>D)8;S4?W1=6O<'ZB"0K!?3:EK8S:.4`D5/3/]*OHG&%I86\&C M8,J]T?&LM.`C)4*V>NKQ]4 MTSR3HD>JHW:SDZV!2RMBE)%R:M)_+M.9,ME+GJ1W&;Y8H0%#'&8?8L@2HI@A M-A,$&P.++LCHPH)5P1XC8D MGN'^:BB],I2&AM:+A?9I4.BJ3N@GA"6;]7<[.-CRCI[@)Y6GIE7H(+0Y/6ZK M*R$T&+'XQHC6YE)/`8-*V^F=K>;/N0^TZ,9;._TZ\B]02P,$%`````@`L'L- M1VF$JCI5`@``N`<``!D```!X;"]W;W)K&ULC57; MCJ(P&'X5P@,,%"B@01(/V>Q>;#*9B]WKJE7(`&7;*K-OOST@MJ2N>B&T?*>_ ME/[%0.@GJS#FWE?;=&SE5YSWRR!@APJWB+V1'G?BR8G0%G$QI.>`]12CHR*U M31"%81JTJ.[\LE!S[[0LR(4W=8??J<D\BD\K?PV6.Z`@"O&KQ@,S[CT9?D_(IQS\.*[\4&;`#3YP*8'$ MY8JWN&FDDG#^,XK>/271O+^I?U/EBOA[Q/"6-+_K(Z]$VM#WCOB$+@W_(,-W M/-8`I>"!-$S]>X<+XZ2]47RO15_Z6G?J.N@G63;2W(1H)$038?)Q$^*1$-\) MR7\)R4A(9H1`EZ(68H4&M7K*Y:"B=EK"2`H M@JL4&C&1PFPLS(0(A+K3(O)M>F30(Y?!UD2DS@P[2R1_'B*^A=##=6SP,VA; M9#JGAG2ZS%#\GKLD,Y?$6LU9L5#;)*8-C'*8N-+L+%AJP1[&@;,XT(H3.^-` MPR?.X"M5IS.;U+)QEK-)S7)RX?/<)IO99)8-=%:3&3:A"[$U$6`!XSA^GB2? M)@5PZKL^>:79J1NM(GH^S^0U8;G5+ MNBY[ICWIYP&PO=V]R M:W-H965TTI=4<%2>TGGW[@:`#9BSK117[OL_O0?H0BH'T[[3$F'D?3=W2O5\RUNV" M@)Y+W""Z(1UN^2]7TC>(\6%_"VC78W09FYHZ@&&8!@VJ6O]0C,]>^T-![JRN M6OS:>_3>-*C_?<0U&?8^\*<';]6M9.)!<"B"N>]2-;BE%6F]'E_W_B>P.\*Q M9*SX4>&!:O>>,'\BY%T,OEWV?B@\X!J?F9!`_/+`+[BNA1(G_U*B?YFB4;^? MU+^,T^7V3XCB%U+_K"ZLY&Y#W[O@*[K7[(T,7[&:0R($SZ2FX[=WOE-&FJG% M]QKT(:]5.UX'^4L&5=MR`U0-<&Z`Z6A<@D:;GQ%#AZ(G@T<[)!8/['AY+T2X MLD='M5[.GANE_.GC`)*\"!Y"2-7(EJ-9LYUK`JZ_"($3))(0J`NDX7.!:!*( MI4!D"`#392)=RII6UN1)&#IP8HL3&QRXR(EUCALFL3")@8D6,8F&X4ERXJ06 M)S4X\2(GU:?CR,FL],YFOK*[(EG.::TW"31\\Q6PNS75M>(!-Q MW.HO9!/%SS$@M#C"L09*ET&J:IZ0`PC8(+"VPM.+4U4S2"[S]`$.7#O0P$QT MYB!A1QJ8F;9VGE@Y-XL`_I$`["G3HAK^C_E:UU#L1QD\5 MXQ'@2@C#7"S<PU'DVI=?3T"``#[!P``&0```'AL+W=O7??@"GRN8:(A!_&QP+R;K0"=_9.Q=;[Z?]V&D<\`$ MGZ260.IQQQ4F1"LIY]^#Z*>G)D[7#_6OIER5_A$)7#'RJSG+6F4;A<$97]"- MR#?6?\-##5LM>&)$F-_@=!.2T0OMDD`VV>$`^$>"3`[+^$ M9"`D'@'8S$Q=7Y!$9<%9'X@.Z=.&SPK.M8A2#H11X_9SJ\<\D4B^)U$DB7A;(/(', M$4AF/Y6+VS74XD]Q+)ER]&Y6#R=-EDYYGLEB]&Y6#R;-D$1IZ+;DD3 MB147&$)?`JXX%P\T7XX+VJVX8S#VDXE7G(T'6E.TWQM@LN)X7-#.;T%@TE,I MYEIEYE:&UL MC5;;CJ(P&'X5P@,,QX(8)!G%S>[%)I.YV+VN6H4,4*:MP^S;;TL!6U)4+Z3] M^4XMV-^TP^2#%@@QZ[NN&KJQ"\;:M>/08X%J2%]PBQI^YXQ)#1F?DHM#6X+@ MJ2?5E>.[;N34L&SL+.UK;R1+\95598/>B$6O=0W)ORVJ<+>Q/7LLO)>7@HF" MDZ7.Q#N5-6IHB1N+H//&?O76^T0@>L"?$G54&5LB^P'C#S'Y==K8KHB`*G1D M0@'RRQ?:H:H20MSX<]"\60JB.A[5?_2KY>D/D*(=KOZ6)U;PL*YMG=`97BOV MCKN?:%@"$()'7-'^VSI>*`=Y`,Q/\@>!/A,G'3`@& M0G`CA'<)X4`(GW4``P','!RY]G[G?4K\Q(_=;Z$T(#Q>\Q6Q42N"9)K,A/"X0&,*7Q;=_`5NC'#3D5$GC'# M0Y']@LABS&",&#^+`A,I5E.]&D1&U MU[22`(#'ZXIGZXJU=<7&[8M5F^7G>0>V&&VWWA^U+P+CU-*G1F M8AB+#9.-2TX8;L*'"%K@$```@$```9 M````>&PO=V]R:W-H965T,O5#+>157I]YYU M5:J+%;R#9TW,14JF_QY`J&$?)=&T\<+/K74;M"KIK*NYA,YPU1$-S3[ZENP. MA:OP!;\Y#&8Q)R[[4:E7M_A9[Z/810`!)^L<&`Y7>`0AG!&"WT;/_T@G7,XG M]R??+:8_,@./2OSAM6TQ;!R1&AIV$?9%#3]@;,$G/"EA_)><+L8J.4DB(ME[ M&'GGQR&<%%]'V7U!.@K268!T%SR`?,SOS+*JU&H@IF?N[I(=EFMG@L[$>#<= MNL>@!G>O%=Y72:_.:*P)DL.R)BFV#;&60 MKE-N0LI0T_F:/-\F\<>8_`:3KQK-UI@B8/(%)ML4\2&ULC55=CZ,@%/TKQA\PXA>ZC369?F7W89/)/.P^ MTY96,R@.T''VWR^(M6AH[8O`]9QSS[T0R%K*/GB!L7"^*U+SI5L(T2P\CQ\* M7"'^0AM``#T*E36;IYUL3>69_0B2%GC-^;P M2U4A]F^%"6V7KN]>`^_EN1`JX.69-_".985K7M+:8?BT=%_]Q2Y1B`[PI\0M M-^:.\KZG]$,M?AV7+E`6,,$'H120'+[P&A.BA&3BSU[SEE(1S?E5?==5*]WO M$<=K2OZ61U%(L\!UCOB$+D2\T_8G[DN(E>"!$MY]G<.%"UI=*:Y3H6\]EG4W MMOI/_*.GV0E!3P@&PI#'3@A[0G@C1`\)44^(GLT0]X3XV0RP)\`)P=/-ZEJ] M00+E&:.MPQNDSI^_D'"F1*2RPSLUIG=0-IO+Z%<>@##SOI10CPDZS,K$0&"# M;$R(/R`\:<#J(G#'&0+3A2W!VD1`W^IA5F0[+[(;B:3SE8372B+=SW#4SVB< M(]'5:DRM,6$*@`VU>0JU,U$A!"F8MQQ-+$<7U4F)V[FYX[!WJIA3[M0W1X3%X#=?U,XBM_ ML?8M\8V_V.JWXB:?9PTZX]^(GX?P_4$L#!!0````(`+![#4??U#GK^R8``#ZA```4 M````>&PO2SUM?4>&@8JB()@2`!$7* M'F_`).611Q)I@?+LQ,8^--$%H*U&-]P'*4[L5XP=\T'ZLLVCJKKZPB&3FH=U MA`\2J",K,ROO2GZ39;DLXO"70ITE19S_^:MA_^0K^7$9Q=F?OUKD^>K%LV?9 M=*&6?M9+5BJ&;V9)NO1S^#6=/\M6J?*#;*%4OHR>#?O]XV=+/XR_^O:;+/SV MF_S;\V1:+%6<2S\.Y$6W)PV/ZEA6?<"D]]N![Q3LW#+$]] MF/?67ZKZJ'1OZ\_NW,C[+&BF=%FM*$,)O" MD?ZN_+1S]X.#P?#@<%#_^%5F".#+OZDH.O@0)W>QG"@_2V(5R%=95JCT/^O3 MWB;K%OHIB8"+_?0>((M:9MNQ?\J`JJLDS<-X+B>YGQ>9U(=J3/I[DS_UAK2) M/(-#SY.T0<_)TH_P^W*CLV2Y\N/&0,,@R7()=V*2)],/GIS0Q9"719[E<'M@ M>B?Y-14T%[R$CQL`_SC<-)MHV#KW[/+MY/+UJ_/Q]<6Y_&[\>OSV[$)._G)Q M<3V!"_Q^P7L$L_#FTC)<>L`7J0#4KUT%/HW813F M81.&\72*@C63*__>QUWP8/YTFA;*`OXYNNQ]>:0[U.@)ESE2[7#=JXO2?;7 MOUR^/K]X-_F3O/CQ_:OKO[=PRDS!-H',\':]D'O]7K_?'R#J)'!7H5[(<9$O MDC3\API>R$'?@Z_Q7ZV@/)9'`1TF*>_D"QF'4?/D=)$K6W7O->IOO]GQZG7E#H#5H1M!N,W.=K-F_\I%1%BH/06`]A0NP)Y]U'+Q& M<*]$_L:1)6TV#N6]-;6V'9UT2W27<=:`7!W6#6]UW%I@6X>N@]2ET^0:_O?F MXBW0Z/*EO+RZ>#>^?@4#Y'X1^P5PH`J>=FN*PZUMO:8>2>(LB<*`N!:UN$*- M!DIS)B]7*B6;KL$:[]2MBIM(O>A0(N]4!IIQRAHI@+E1LB*]V:5UOE>Q0CN/ MA':P#&.R'?/P5FU05`F##**U:]Q;!6(YR9KFB)_&,`\4!I@;1#Q`]XV?A5.& M.HR*O(G:U[`2S9AJXN/$^J"_J7"^0/3ZMP#=7/T^WC@;3_XB7[Z^_-N6O$&F MP"Q*[C(Y2Y.E@R)0+.%MN\8-?BZRG!DA3T!)@NZ9@J$F8XT]_!1_GFZQ^(N& MO0`67)@2`[11@HPW1+U"G;=$,K*GTZ'JJ^/CK(AF"@PIT+N?9:-\WJ2:D=(4]UTV0M9EH[S=DG";.&D6QCZPQ7IB M7Z7)5*E`3\G`"I7)S%X7(MTJ`L_ASD_1.VQN2O22I'6WM&D[C5]/WH`;&N,] M1R!69.SO,%NA+=$U[S*=^W'X#V)5#YS_`YHCN)7B7 MJ(N+FRP,0G01]V&8_/2K=LH^_?;4DS/T?U"ZQ1*_]*>`P2QD\%*M"#Q7"PB` MUI/AS+"`@M^0/U2**-!'PR/X19Y$R3P!;MDO,N([8''@NCC_],\,@9-3\(*S MI_0_,,12A"`%8PW1NO"1ZV-@`5F@J)@EJ5BJ`.T@OG+ULT9>$C)$<]K-?`6DCL4/!6P[&)(J/_1H4PT;_I(FQ7PMO3Q9$EM.IH"Y M*>QYEJ2KGMS_]&O+ETA2@5(X4BB!:A3%4^%VL\B?9XMP!0[-=!$CD6`K7^:I M\DF+R"7P4Q+0%XAXF7T`E(5@>&B^S5:I?T\414ID60*DQ_WP^C&3X"SH]N5 M)46*?(IZ@STO/C7"X$QQ]J50[9"E"E&K+5M\3X=+MF+'/Q\:-G%6D M/P-`*F0^9@`"M4*5`#@#60-*"O4SRCU$)%L1]PA65DP!_&Q6X)5,_3!3YAR" M3M\X*,R9%26E-%J>):G78((2Z43'&C8;<=1).(]#P!C&8;7U@8QP!1[`M$7C MDY(9]N2.T[X#LSD3@,4K%/AQ7DK$JQ38,P1A0M1TE@+LBQ!D?QHNR8BS+LG, MZL*L=$Y@D:@`3T<"GRA`_P(L:V`'%:-T!BK`-S?W5>F(J@P,;DD&LX)@IM5^N(7'Z=LFZ#C%V89GA&$Z.3B#(2F M7!5I5OC,EU?(%\-!'Q=Z9]>5DX/_ZHDSD.X^"D,GI(^KSY(DCQ']09A-X387 M*0F$%`.B]R4"8&8KABP>F@>EWQGMH'DL/9BS<''X7JWR4JV]CT/K'#+=0#<# M,^!IOQ^/K_"X)06`>@$:KL"^J4R684Z6JX,-N`X+`5AJ1S8(B@@I!8K,O8-- MZ>/BQ:(#59)[FLI M.;RJ8"%SSB=_.#,0H]`E?B*2-/<"W@+(MD993]3UM,+(C<^,Z%R.&[S&:-,` MF2F(<*O%NH]*:NHO@05N_3`BCPIXH+`BG_F&6`/QU0*$N`-J@6;&^`ZJA#"K M[,V.&`EHWA48`TS6#/T?$A2IG);^Y31,0>NCBS\UC'N7%%%@U!%!EFAN0)"$ MOV1_,*5T1WD#6UD,R9Z8:Z!:<`37"#[?%5"F@V8*66$*8C4CI=D+RN"*W9.A M+6_`'C")&7,I$0\`U"Q!S0W_JK1Y(9(9!E$`S(OS[\?O>HXZQ-M7AN+P M)->(`K%9TK3HOA:9_WXB4533K=;24AOS.@11MWEP'-Z''1P),(B!I)EC*Q"O M3/62%0;$]8UMZ!P!I#PX2'C8GK.#L*X*.F``/C@LZ#LI%]&1?U=J:D0/_O(6 M9$C@(\;)?#.>$T#*/AZ(".%8(=\7(>-L'-\+BCWCMOH69IH[Z,[:Z8XVE7,S M'<3&4FEU1\O@#X1N#C3G?$GB)#Z8)[=@_"$I@:R62IE@/M+WOPP(.,!.,';H MIW`%OTO@?\AAK=^>)0'1(R]/ M#99H-?B'-`&OJ$T'7I*4;V`<8)C)B*3P`^?`6=):N8L?1F#KD&L(7VJCE44; M*H@&/#V7N,C+:C934^)85P&0JQ['!=DI)CUOM$(9:"/O25BQB2XR+/V<)8R! MDNZ30HSG:9*M>+?H?J-/3)(#O].T()\<#4S//8,@;PUGVO%\)!.DS]0"BZP#E;1(78(0NR;Q!9XR5B;4CM_')Q MM,ZM=:\LV#IV5"Q73#3"E6_PIDJKRIA9&%-LC?SC[Z)K2B7\8J/T09$:&Z)^ M&Q#+.5\3(@W8UC!>8?*?/`1P577@P=AJ8$L($&BH.$BDLO:Q)^U)#%(332E: M?5$&J8EVAAV-K,C(ZUB$\P4@/0IA-*(\R]-".XM%"E(!91.3#2B>AL#)`/(2 M`\I(4-*LJ5)RR9E&X&8J/>#[6X^5@U_;%48G0PE]N'")DO4C9@?D3`6:)P"N M`FT8-`0PQO82O!KQ$Z9P$8126;URX,4` MCK(J\`@F_4D$.W=BPF=)5J,8RM8X(*QB=I#B0>96=Z109P!$7F%&FR^:TOIL M,E&@LV[MX@!`*SJ]Q0P.PCP,R`@*N#.D(A2YIA[08PIKX]Q)<]F2"6*88BF2+\9;)'P8F"=G!KX:G+?UQ2I;I0/L, M3._D#G'W"QS=&(U(IR0U"0WRA;2,HRMOTV4V)'!K+@_'0:K@O8!9?G2OXW5D ML]@0/H5/3641R@<07&4QC.8,)Q"!HL`*P7(9EM1X.[QZ1H32NSH013R'\9#2 M+]44(6$^]2EK`[(R`++>5P=6XD?.YP@(;VU=.0+$A[P65PM]QXGI[\ MSH@(OT(C)B.>TG-5%F;1.4[%JDGKX5N\`9FBTBV3HEKZ@;*ROV-M7H4S"4MP MF^&.?L#X$7PQ?.94$\Q!0&U8LP5GI!F2)N2(V@8+!#TIK8`Y0Z6, M26L5L6M.4I82AW\7^7"6R11<7477E'+:RP08#1`DK*9NN5*;T-!V6(9BW:8M MYHXPYHYKX`#;PRZ4S:9/@`%N,=5B8RVWE&##/`3'\](P^P!.OPLQ'[L;T5,QRW9?E%WCMG'0L!E<"9RGMCG% MSUFHXSQ8@>^[GXLP,XX7&ZC,_J3)M$R$Y0-3GU;BIL.D!*I7D(*!$XM;1!H< MX&Z!$.%]%JWW>3_LJ9[''X>+)`F8IY2?$^/#J%'_"?C6)1U0:)'214.:HH!& M)%BTW)EP6@8N*(>LBU42"_71IU`,CL%DBO^1;K0.8+2#[]E6P,."G,C!2<:+9JX"L[F@A`*[,3IVJ8&-M21UR7PO+;#: M<=?WF(52&6$`*"SG=+,,E2CHN@(=.RU9%<4A!2$`\!P&"#G%"YC(^>^PKSDO8XN3"-8/IS=ER*/ M;'\%-@PAV56%U1N:"3M%ZR+,A.+Q:_OA9RL^4LSYK7(S.'2Y5TD88Y'7(AS@ MF.%YD6PIL'[LRA7@K-N0LHR.KVGB+3:G!5\J4YT'L\AIX6*`GC0UCF(?ZQ:? MXFL'?B-1D?AZJ8SK51HED%(U*R7W/_UZ<37!B)OVOL@R@GGP*9(!)-!45S^@ M`1?>A@&;CB!F^8#[$4&DL[9W]8K)N*#@D5,YUBBA;&*E1$I/GFO@$2#C(6)D MF44ER8#M-F:OAGYTRAQV!>9`>C0S'4UTV8JWBC1L/^YNVI24')R,< M)OC[YKY`MC6<[L%=M5B4F[!(B3V\6V[JG'W@);CI7(B% MP/5.2I6)-2T'9@8Z^L3C`O/]]_+:S7>,JT6 M)!+U928'H,-`EI!X;.9:LVII`GP+5FJXQ/HV#FHL0:>H[&M8'S:H3G92WO0] M#$`QG0"U0G3UGPF1K&L?YZ?#4&W0I:PSD%QR32I65V9["'EH,3JMD[ MU/+8Q,KHR1^Z/L"[%`F&\Y+Y]T+N^T_EWD"/![@:4AEDQ`T,&76.&'TM]J=K M1QQ_3TQEM`M;_OH-'L#7E74)T1)/#^HO_0SV@=]"SH>.99NB$-G MQR6]#,>\EC"2H)H"-($MA_7.["L(84+"]2@MU[.E",E8_HV-"HT(MH7W^JX% M4PG],Y]5U?D^LL8+0,+IR#L\/'RJJSF$5KMKXM>[`+@+1)C"<3\YP@)JB;GO M04NIKA$U@D4-Y89U4*6\LOI:6V^504D2JL?Z7;.%,$ M^=[PB%YXVEMJI-5487FTH=/<9N\9B>VTN,/4V8\<8E@`F,C%^5-427R`? M7*-<>A5C03SRW!7(''YG$.,H5ZES(0@J13(!,06A^8[+3]#Y"Y(5&>:@V'^F MK"N52RCP]P`'9$?SVU6.DP!`7@LXH@:.WJ7Z*>E#)%5M,#G)@4[-4>@[R^P; M&/8$C",#'Q0K!'%H'P\+[3SL.P%1\#LW98CPZVNZ?MY@1__*!` MOBQ747)?ILY(0OMEY96PQJJ)O<_Y,0P)`#NYK'>J'MS-[-F=V3[6$)%IC>:. M7KPP\`%*]B+)8"([5G+:3043M]QBH<.@)A!+ MZ:AJBJ+DP6ZF(WU$;P68A,8RG)L76+@0!S]0:&AD33'%PJ=1**T3'?6ZU;E` M-I"-"ZJ5@W%,M!TU05A=1FAC# M5@&8&V1S@)>-D1%=BV$LZ88D$JN:LF^YVRY$0+BH#,+GX`SC;IE^3].>%Q-Z M`<4E%DX`IA[0P?/6!5"GV#'L;3-X%:HU.$A4=FI+XGDZ#T`1I"C)=(W3M"TX MT[98Y".14I\%MG]O"\1$RU9(F%6NB^_,N:KK.J)' M#*#0G0MP&Y(-G'KH((K+'Q0PN)+OPDB1N,1`!#G].8:8Y#@` MZ9N`O\@2E@L326>\P>H=FF7OD2M'Q'-O5$J.#83GA+]AD;U![^BP1*>W`R-I M.0!Z0!!(-/.%< MFM2*)OF[T#0<.6@2.]^W;C2Y%>':[G=U0'1O[K>^8T*K'W,E=-W'IU^QN(RN M`&7!/_WFB`8LARPBWWD.E.OW0/3HV3$S22=B?!7,5S"(6`CQJ\[`EC'4PZ=; M0$VZ&2&UIE0E!%^ORQUY1@/I`MPQ%08UW[BB",#_#$Z]DUJTWSZ^04FB1;M; M5H+ED-@NX)X$?EGEE-.DK%ABF125@3@BSO08*-\[-?PI"^`+85INB#'G<>P' M\IW"[GJXW=CH<5OMH@?;"O:"Z@Q!B,19.!5.&S%YH7E`7!$/O@YG2NQC^Z_L MJ:1B1?&=#M_H6)30_J7)><@]V>^=',K3WF`(/Y\>>8-17]1-_P&/'?0.C^0` M>R#AM')IUX>4)N=""_?E2>_D>;GP1:F6A5^+A\F!.W,`,Y\/X.?1H3<<]9E$ ME9H7XM0*:3@;3/63UNRIUO>4-Z):]V(<;+?\18>.-'MQAJA=V>T0#O*J0HC. M0+IRJ4R"KR9%2L$GJ@J"+YW)%!Z83&%+85`#8+CWA'&*_99%I]$]"CJ`S@JZ MZAYBESTT4BB.C/O@RB-WY7%K!9%;*E16RH`MZPF22?C0^3Y446`+B0Z:A42Z MJD579IJ+6B5Y26-G3Z>L258*B4K'&&FR`*\K2:F@!6%,*6[/:W5!Y*[FR_>] M28_:$F1%2L_6M$RU9/W6 MK+-4LL2V.0RW1:AJ?ZZG=-P<%WU9-:M?-ME;MU\EVS'P3DZ/.8_3]T35!#*' MS<*/#WY4V754\66.6K/VN-Y";*=1M]P.3"#\3>X-#K'QV3`J:#%[%S ME,K)Z1F`(\+M[A6@S`/6,*O7%3OKWMRSC"M1FBULS0J)H9:BW<`)2U!@4J91=8I`'"OY8+U='*&=(Z)`QAOL%).>IR M!^Q9JGN^833'ADZ3&7A$?5V=5L0A*U%N:.I6,^GD#[X,S"C%5`\/:*L9!_#V M1-YY2M5;IO<<#37;]<0%6O\TPS[.00T>JXY0(Z4.8IN//M?)MBMS2I.>-JVG MS##].0(N?.OEPA@=H*OD6-W==PJ0#!R_@5^D.>8F$H@MJ:_=E'H)FPE-C%9RFK]GN\Z MF?;5L.M"C4YU#:,.U+2>LFB+YII06+X43! MZ5!3]]ND!LE)6B78R6FN`F5C*L*QXEYT/?]`(,$B'SWQN$Y/1S[(#M(KS+L;&QZS].H8(J4,/VT]%'QU2>@EOXJ@5/G=(E_ZV"5 MCP#)"@&<($RS=I789YG-T4Z7SBZ2']/ M939K2WR$20;SVU8N3D`Q6<(1)+'MY5#;WM2(6:U9OGG9>\ZA00T3'<;41(@& MY7`0GQ=;0*"CMZYN!LP]6+U>-V.*8.AE8D*/JVZH6X^\!+8@"F#(R;R/-8WCQHK4ZEXU%0%]MQ*((\](YN(LE6`MD:3.-9YN*A0\&:)+JZ5S]?5 M8_<^_=9L@]I5B=LJH=;6[C;J;RBC6-J8VDX*;<\-([@IP.@1'OX:IA\B[K$1 MR#>8G`E!#"S"A,FJ%0E95:8)!Z484K?V25=+87DJ-D7CG'B=YJC\TY13L_@T M)M6]=:D MV3&S;#1W<=MIKYQ03<_Z@;96?G,>]EV("B*`*[_$[K:[I*PICVM^*AV][^SFY4G]_V5N[8]E8\ M2MM;V6Q[*]O;WI*>?^RVM[*[[:UX_+:WU=Q=V?96?*FVM_7V].+?T/96NFUO MQ9=N>ROK;6_-:[HOVO961R-;>B%_L;:W.,!M>RN^;-M;#LQRVUNZ^8_4]K;Y M)V)<95GI@MNB+S/5<:E<;#UJ4]S.1ZSB2S;%E9U-<<5G-L5M>35DFMRV],AM MC*9F0=NTS!6/TS)7[M`R5^S6,E?NTC)7/%S+7+EURUR1/F#+7+EKRUSQ\"US MD5&W;YDK'J-EKMRA9:YX\):YC=+<+5OF5MKH?W;+7/E9+7/%`[3,E;^C9:YX MP):Y70?H^"-N5!5L&K2VN7EK&NJ*+])05R9K&^K:#G./U5"WM:&N M7-=0M_./P-7[Z[91=EV[7?%EVNW*SG:[8J=VN_7C8?==N;[[;AM&=FO&*QZZ M&:_L;L:[]D^3-GKSKJ/VQE:]XC%:]\8!]>LV(+?OTB@?MTRMW[],K'K)/K_R\/KWB@?KTRL_J MTRL>JD^OD^YN_R.X'>T?7,[MZN);35`_>!=?N6T77_$X77SEEEU\6]'0=MC/ MZN)K8[/KNOB*S^[BV^P+1KT5J:EO"T_\T>/WCQZ_?_3X_:/'[__?'K^"#.Y_ M2X]?P2WBY`/W^*V+>=/R5]9;_JZS$5HZ`(M'ZP!LCM_>`5@\=@=@N:$#L'C\ M#L";>M>*Q^T`++?H`"P>MP-P5S76T\J+M"_0`9BD=GL'8+%%!^!&;/"/KK]_ M=/U]K*Z_;8W_Y/XU1=$:)4ZM@WGL.E?2MNJH#9(?E]&+;.5/U9^_HNN8WJJO MOOU273=DV75#KNVZ(1^IZX;M&LQAU;=>-9@&Y;8]0:_Q@^Z+4IW0_S^_L M`X#/\^66S_/EQN?Y8WR>;Z?]M.OS?.D\SV^4TJ9S/S;/8=[Z9#!3M)X+.$V_ MQ\LRF;-_CM7Q40:C4WZBVK@B0)Z>)<_[R;G-V76LC,&>?\X<'&DC:VD[X[$;F'5CIH-JK6EBM"3')VI;.SNT#L:.S MK'=T;J+2%O)_5A/FM9D*-S[;'MO?:>WSU);9_O<;,L'^9SMMHZF`N#]N/`8H M;U,W::[QN6X7`SFROVN(:V\?."ET74;3-4V+^NY5G445_[!A1:?Q87U(0_Y6 MF^IM=[3U4#1%O%6XYDFGXG8^C9GF7N^(R5.M``9,=CDXQ#:&C5LPZ/.X+;== M?\H3LV??\%K'KG;U-50QBYW8M8Y;U[(&"RI+-DHX4;>@?0MU9"[T$;N/`0``J!```!,````` M`````````(`!`````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"%`,4````"`"P M>PU'2'4%[L4````K`@``"P``````````````@`'``0``7W)E;',O+G)E;'-0 M2P$"%`,4````"`"P>PU''[$)[DD!```R#P``&@``````````````@`&N`@`` M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"%`,4````"`"P>PU'-NT) MUF,"``"^!P``$```````````````@`$O!```9&]C4')O<',O87!P+GAM;%!+ M`0(4`Q0````(`+![#4>BO(XS/P$``&D#```1``````````````"``<`&``!D M;V-097)PC$`8``)PG```3 M``````````````"``2X(``!X;"]T:&5M92]T:&5M93$N>&UL4$L!`A0#%``` M``@`L'L-1YW0N@1;`@``>`L```T``````````````(`!;PX``'AL+W-T>6QE MPU'IF25'OT"``#7"```#P`````````````` M@`'U$```>&PO=V]R:V)O;VLN>&UL4$L!`A0#%`````@`L'L-1XC^WC=N`@`` MP`@``!@``````````````(`!'Q0``'AL+W=OPU'*<#R MPC`"``"5!P``&```````````````@`$Z&@``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`L'L-1WHW]L_6`@``DPH``!@````````````` M`(`!H!P``'AL+W=OPU'%+$0=J,!``"M`P``&``````` M````````@`'E(@``>&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`L'L-1U@H4M^C`0``K0,``!@``````````````(`!OB0``'AL+W=O=M*,!``"O`P``&```````````````@`%Q*```>&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`L'L-1RLPPU'97?/-:4!``"P`P``&0``````````````@`$E M+```>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`L'L-1P=.Z.>D`0``L`,``!D````````` M`````(`!W"\``'AL+W=OPU'&,Y&5CT"```:"```&0``````````````@`&W,0``>&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`L'L-1TQH=DF-`0``/`,``!D``````````````(`!%#8``'AL M+W=OPU'3N=84;D! M``!&!```&0``````````````@`'8-P``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`L'L- M1UFD"RR(`@``+@H``!D``````````````(`!5#P``'AL+W=OPU'DVI=?3T"``#[!P``&0`````` M````````@`$3/P``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`L'L-1QXH<(6N`0``"`0` M`!D``````````````(`!&40``'AL+W=OPU'^AKY`DD"``"0!P``&0``````````````@`'^10`` M>&PO=V]R:W-H965T v3.2.0.727
Common Stock Options
6 Months Ended
Jun. 30, 2015
Notes to Financial Statements  
Note 4. Common Stock Options

Approval of the 2013 Long-Term Incentive Plan

 

On June 20, 2013, the Board of Directors (the “Board”) adopted, subject to receiving shareholder approval, the 2013 Long-Term Incentive Plan (the “Incentive Plan”). The Incentive Plan provides for the issuance of stock options of up to 20,000,000 shares (subject to adjustment) of the Company’s common stock to officers, directors, key employees and consultants of the Company. Options granted to employees under the Incentive Plan, including directors and officers who are employees, may be incentive stock options or non-qualified stock options; options granted to others under the Incentive Plan are limited to non-qualified stock options. On November 15, 2013, shareholders owning a majority of the Company’s issued and outstanding shares approved the Incentive Plan.

 

The Incentive Plan is administered by the Board or a committee designated by the Board. Subject to the provisions of the Incentive Plan, the Board has the authority to determine the officers, employees and consultants to whom options will be granted, the number of shares covered by each option, vesting rights and the terms and conditions of each option that is granted to them; however, no person may be granted in any of the Company’s fiscal year, options to purchase more than 2,000,000 shares under the Incentive Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the Incentive Plan are exercisable no later than ten years after the date of grant.

 

The exercise price per share of common stock for options granted under the Incentive Plan will be the fair market value of the Company’s common stock on the date of grant, using the closing price of the Company’s common stock on the last trading day prior to the date of grant, except for incentive stock options granted to a holder of ten percent or more of the Company’s common stock, for whom the exercise price per share will not be less than 110% of the fair market value. No option can be granted under the Incentive Plan after June 20, 2023.

 

On May 29, 2015, the Company appointed Patricia Jeanne Riley to its Scientific Advisory Board and issued Ms. Riley an option to purchase 7,500 shares of the Company’s common stock at a price of $1.43 per share, the closing price of the Company’s common stock as quoted on the OTCQB on May 28, 2015. On June 15, 2015, the Company appointed Dr. Steven Wang to its Scientific Advisory Board and issued Dr. Wang an option to purchase 7,500 shares of the Company’s common stock at a price of $1.25 per share, the closing price of the Company’s common stock as quoted on the OTCQB on June 12, 2015. The shares underlying the options may be exercised on a “cashless basis” using the formula contained therein and, subject to each individual’s continued service with the Company. The shares underlying the options vest on November 30, 2015 and December 15, 2015, respectively.

 

As of June 30, 2015, there were 19,800,000 shares available for grant.

 

Stock Option Activity

 

The following table summarizes stock option activity for the period ended June 30, 2015:

 

                Weighted        
                Average        
          Weighted     Remaining     Aggregate  
    Options     Average     Contractual     Intrinsic  
    Outstanding     Exercise Price     Life (Years)     Value  
Balance January 1, 2015     185,000     $ 0.83       9.12     $ 94,150  
Options granted     15,000       1.34       10.00     $ 0  
Balance June 30, 2015     200,000     $ 0.80       8.87     $ 94,150  
Exercisable at June 30, 2015     100,000     $ 0.81       8.71     $ 53,250  

 

The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. There were 15,000 stock options granted during the three months ended June 30, 2015, 7,500 shares each to a member of the Company’s Scientific Advisory Board. The weighted-average fair value of stock options granted in 2015 was approximately $1.00 per share. The weighted average fair value of stock options granted during 2014 was $1.05 per share. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company’s historical experience. The risk-free interest rate is based on a U.S. treasury note with maturity similar to the option award’s expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The assumptions for volatility, expected life, dividend yield and risk-free interest rate for options granted are presented in the table below:

 

  2015 2014
Weighted average risk-free interest rate 1.49 – 1.71% 1.43 – 1.62%
Expected life in years 5.50 4.50 – 5.50
Weighted avg. expected volatility 94.4% 99.5 – 105.3%
Expected dividend yield $0 $0

 

Stock option expense reflected in the consolidated statements of operations related to stock options issued to our non-employee scientific advisory board members and consultants are recognized at fair value using the Black-Scholes option-pricing model with weighted average assumptions described above. For the three months ended June 30, 2015 and 2014, stock-based compensation expense recognized from stock option awards granted to non-employees included in total stock-based compensation expense amounted to $1,896 and $0, respectively. For the six months ended June 30, 2015 and 2014, stock-based compensation expense recognized from stock option awards granted to non-employees included in total stock-based compensation expense amounted to $1,896 and $0, respectively.

 

During the three months ended June 30, 2015, total stock-based compensation expense of $9,719 was recognized as general and administrative expenses. During the three months ended June 30, 2014, total stock-based compensation expense of $12,573 was recognized as general and administrative expenses. During the six months ended June 30, 2015, total stock-based compensation expense of $20,663 was recognized as general and administrative expenses. During the six months ended June 30, 2014, total stock-based compensation expense of $19,355 was recognized as general and administrative expenses.

 

There were 100,000 stock options vested and 100,000 stock options unvested as of June 30, 2015. As of June 30, 2015, the Company had $13,046 of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized by June 15, 2020.

 

The Company issues new shares when options are exercised.

XML 14 R8.htm IDEA: XBRL DOCUMENT v3.2.0.727
Intangible Assets - Intellectual Property
6 Months Ended
Jun. 30, 2015
Notes to Financial Statements  
Note 3. Intangible Assets - Intellectual Property

On July 12, 2013, the Company, together with its wholly owned subsidiary, RenovaCare Sciences, entered into an asset purchase agreement with Dr. Jorg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlach’s rights, title and interest in the SkinGunTM. The Company plans to further the development of the SkinGunTM and, if commercially viable, bring the product to market. Acquisition related costs amounted to $52,852 and were capitalized together with the cash payment upon the closing of the transaction in July 2013 of $100,002. Additional costs capitalized during 2013, and which related to an option to evaluate a wound cap technology, amounted to $10,000. The Company allowed this option to expire, and during the period ended March 31, 2015 recorded an impairment loss amounting to $10,000, which was equal to the amount capitalized. Intangible assets amounted to $152,854 and $162,854 at June 30, 2015 and December 31, 2014, respectively.

 

The asset purchase agreement was amended on June 9, 2014 (the “Amended APA”). Pursuant to the terms of the Amended APA, an additional $300,000 will be paid in four installments: (a) $100,000 on December 31, 2014; (b) $50,000 on December 31, 2015; (c) $50,000 on December 31, 2016; and (d) $100,000 on December 31, 2017. The Company paid the first installment of $100,000 in January 2015. At June 30, 2015, $50,000 of the amount payable to Dr. Gerlach was recorded as current liabilities and $150,000 was recorded as long-term liabilities in the accompanying consolidated balance sheet.

 

As further consideration for the SkinGunTM, the Company issued to Dr. Gerlach a Series A Stock Purchase Warrant (the “Series A Warrant”) entitling him to purchase 1,200,000 shares (each a “Warrant Share”) of the Company’s common stock at an exercise price of $0.35 per share. Pursuant to the terms of the Amended APA, the Series A Warrant will vest in five equal installments of 240,000 shares on each of July 12, 2014, July 12, 2015, July 12, 2016, July 12, 2017 and July 12, 2018. Vesting will no longer be contingent on the achievement of certain milestones and on Dr. Gerlach’s continuing to provide consulting services to the Company, but instead on passage of time. Prior to September 9, 2014, the effective date of the Amended APA, the value of the Series A Warrant was recognized as consulting expenses over the vesting term. Effective September 9, 2014, the Company measured and expensed the value of the Series A Warrant in full and recorded this value as research and development costs. The fair value of each Warrant Share as of September 9, 2014, using the Black-Scholes option pricing model, was $0.91.

 

Consulting expense associated with the Series A Warrant amounted to $0 during the three months ended June 30, 2015 (2014: $195,333). There were no research and development expense associated with the Series A Warrant during the three months ended June 30, 2015 and June 30, 2014.

 

On May 1, 2015, the Company entered into a new option agreement (the “Option Agreement”) with Dr. Jorg Gerlach, pursuant to which the Company obtained a one-year exclusive option to evaluate a wound cap technology (the “Technology”), for the purpose of determining whether the Company would like to purchase or license the Technology. Pursuant to the terms of the Option Agreement, the Company will pay Dr. Gerlach a non-refundable fee of $24,000, payable in four quarterly installments of $6,000, with the first installment due on May 1, 2015. The $24,000 option payment was recognized as research and development expense during the period ended June 30, 2015.

XML 15 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727
CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2015
Dec. 31, 2014
Current assets    
Cash and cash equivalents $ 1,162,565 $ 683,098
Prepaid expenses 29,317 7,448
Total current assets 1,191,882 690,546
Intangible Assets 152,854 162,854
Total assets 1,344,736 853,400
Current liabilities    
Accounts payable and accrued expense 14,062 6,182
Accounts payable and accrued expenses - related parties 41,925 7,255
Contract and contribution payable 105,500 187,500
Total current liabilities 161,487 200,937
Long term liabilities    
Contract and contribution payable, less current portion 159,375 178,125
Total liabilities $ 320,862 $ 379,062
STOCKHOLDERS' EQUITY    
Preferred stock: $0.0001 par value: Authorized: 10,000,000 shares, Issued and outstanding: nil    
Common stock: $0.00001 par value: Authorized: 500,000,000 shares, Issued and outstanding: 67,585,122 and 66,575,122 shares $ 676 $ 666
Additional paid-in capital 9,159,513 8,128,860
Accumulated deficit (8,136,315) (7,655,188)
Total stockholders' equity 1,023,874 474,338
Total liabilities and stockholders' equity $ 1,344,736 $ 853,400
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.2.0.727
Organization, Nature and Continuance of Operations
6 Months Ended
Jun. 30, 2015
Notes to Financial Statements  
Note 1. Organization, Nature and Continuance of Operations

RenovaCare, Inc., together with its wholly owned subsidiary (the “Company”), focuses on the acquisition, research, development and, if warranted, commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications. The Company was previously involved in the exploration and development of both mineral exploration properties and oil and gas properties.

 

On July 12, 2013, the Company, through its wholly owned subsidiary, RenovaCare Sciences Corp. (“RenovaCare Sciences”), completed the acquisition of its flagship technology, a treatment methodology for skin isolation, spraying and associated equipment for the regeneration of human skin cells (the “SkinGunTM”), along with the associated United States patent applications and two (2) foreign patents, the first of which expires on August 22, 2027 and the second of which expires on April 26, 2031.

 

The Company has recently incurred net operating losses and operating cash flow deficits. As of June 30, 2015, the Company’s total accumulated deficit is $9.2 million. The Company does not currently generate revenues and will continue to incur losses from operations and operating cash flow deficits in the future. Management believes that the Company’s cash and cash equivalent balances, anticipated cash flows from operations and other external sources of capital will be sufficient to meet the Company’s cash requirements through June 30, 2016. The future of the Company after June 30, 2016 will depend in large part on its ability to successfully raise capital from external sources to fund operations and/or, generate revenue and cash flow from operations.

XML 17 R22.htm IDEA: XBRL DOCUMENT v3.2.0.727
Commitments (Details Narrative) - Jun. 30, 2015 - USD ($)
Total
Commitments Details Narrative  
Incurred expenses $ 44,910
Other current liabilities 37,500
Other long term liabilities $ 9,375
XML 18 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 19 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727
Significant Accounting Policies
6 Months Ended
Jun. 30, 2015
Notes to Financial Statements  
Note 2. Significant Accounting Policies

Basis of Presentation and Principles of Accounting

 

The interim consolidated financial statements included herein have been prepared by the Company, without audit, in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) pursuant to Part 210 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to such SEC rules and regulations, although the Company believes that the disclosures included are adequate to make the information presented not misleading.

 

In management’s opinion, the unaudited consolidated financial statements contained herein reflect all adjustments, consisting solely of normal recurring items, which are necessary for the fair presentation of the Company’s financial position, results of operations, and cash flows on a basis consistent with that of the Company’s prior audited consolidated financial statements. The Company has evaluated information about subsequent events that became available to us through the date the financial statements were issued. This information relates to events, transactions or changes in circumstances that would require us to adjust the amounts reported in the financial statements or to disclose information about those events, transactions or changes in circumstances. The results of operations for interim periods may not be indicative of results to be expected for the full fiscal year. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements, including the notes thereto for the year ended December 31, 2014, which may be found under the Company’s profile on EDGAR.

 

Principles of Consolidation

 

These consolidated financial statements have been prepared in accordance with US GAAP and include the accounts of the Company and its wholly owned subsidiary, RenovaCare Sciences. All significant intercompany transactions and balances have been eliminated. RenovaCare Sciences was incorporated under the laws of the State of Nevada on June 12, 2013.

 

Applicable Accounting Guidance

 

Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board’s Accounting Standards Codification.

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) 605, Revenue Recognition. The new revenue recognition standard requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for interim and annual reporting periods beginning after December 15, 2017 and is to be applied retrospectively. The Company does not currently have any revenue. As such, ASU 2014-09 will not have any effect on the Company’s results of operations and financial position. If the Company begins generating revenue prior to the effective date of ASU 2014-09, it will evaluate the effect that ASU 2014-09 will have on its results of operations and financial position.

 

Accounting Estimates

 

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results, as determined by future events, may differ from these estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents may at times exceed federally insured limits.

 

Fair Value of Financial Instruments

 

The carrying amounts for cash and cash equivalents and payables approximate fair value based on observable quoted prices for active markets – Level 1 inputs.

 

Research and Development Costs

 

The Company intends to outsource its research and development efforts and expense related costs as incurred, including the cost of manufacturing product for testing, licensing fees and costs associated with planning and conducting clinical trials. The value ascribed to patents and other intellectual property acquired will be capitalized as it relates to particular research and development projects that may have alternative future uses.

 

Intangible Assets

 

The intangible asset consists primarily of SkinGunTM technology that the Company acquired during 2013 and is recorded at cost. At the time of acquisition the technology had not reached technological feasibility. The amount capitalized is subject to impairment testing until completion or abandonment. Upon successful completion, a determination will be made as to the then useful life of the intangible asset, generally determined by the period in which substantially all of the cash flows are expected to be generated, and begin amortization. The Company tests the intangible asset for impairment at least annually or more frequently if impairment indicators exist after performing a qualitative analysis. Management has multiple criteria that it considers when performing the qualitative analysis. The results of this review are then weighed and prioritized. If the totality of the relevant events and circumstances indicate that the intangible asset is not impaired, additional impairment tests are not necessary.

 

The Company assessed the following qualitative factors that could affect any change in the fair value of the intangible asset: analysis of the technology’s current phase, additional testing necessary to bring the technology to market, development of competing products, changes in projections caused by delays, changes in regulations, changes in the market for the technology and changes in cost projections to bring the technology to market. Based on a qualitative assessment, management concluded that a positive assertion can be made from the qualitative assessment that it is more likely than not that the intangible asset related to the SkinGunTM is not impaired. The Company did, however, determine that an intangible asset related to wound care technology, acquired during 2013, was impaired during the period ended March 31, 2015 and recorded an impairment loss (a component of research and development expenses) amounting to $10,000 which was equal to the amount capitalized.

 

Stock Options

 

The Company measures all stock-based compensation awards using a fair value method on the date of grant and recognizes such expense in its consolidated financial statements over the requisite service period. The Company uses the Black-Scholes pricing model to determine the fair value of stock-based compensation awards on the date of grant. The Black-Scholes pricing model requires management to make assumptions regarding option lives, expected volatility, and risk free interest rates.

 

Income Taxes

 

The Company recognizes income taxes on an accrual basis based on tax positions taken, or expected to be taken, in tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. Should they occur, the Company’s policy is to classify interest and penalties related to tax positions as interest expense. Since the Company’s inception, no such interest or penalties have been incurred. The Company did not record an income tax provision during the periods presented due to net taxable losses.

 

Earnings (Loss) Per Share

 

The Company presents both basic and diluted earnings per share (“EPS”) amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. Potentially dilutive shares of common stock consisted of warrants to purchase shares of common stock (9,210,000 shares as of June 30, 2015 and 8,200,000 at December 31, 2014) and options to purchase shares of common stock (200,000 shares as of June 30, 2015 and 185,000 as of December 31, 2014). During the periods presented, potentially dilutive shares of common stock were not included in the computation of dilutive loss per share as to do so would be anti-dilutive.

 

Related Party Transactions

 

A related party is generally defined as (i) any person who holds 10% or more of the Company’s securities and their immediate families; (ii) the Company’s management; (iii) someone who directly or indirectly controls, is controlled by or is under common control with the Company; or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. See “Note 7. Related Party Transactions,” for further discussion.

XML 20 R3.htm IDEA: XBRL DOCUMENT v3.2.0.727
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2015
Dec. 31, 2014
STOCKHOLDERS' EQUITY    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, Authorized 10,000,000 10,000,000
Preferred stock, shares Issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.00001 $ 0.00001
Common stock, Authorized 500,000,000 500,000,000
Common stock, shares Issued 67,585,122 66,575,122
Common stock, shares outstanding 67,585,122 66,575,122
XML 21 R17.htm IDEA: XBRL DOCUMENT v3.2.0.727
Significant Accounting Policies (Details Narrative) - shares
Jun. 30, 2015
Dec. 31, 2014
Significant Accounting Policies Details Narrative    
Common stock consisted of warrants to purchase shares 9,210,000 8,200,000
Options to purchase shares of common stock 200,000 185,000
XML 22 R1.htm IDEA: XBRL DOCUMENT v3.2.0.727
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2015
Aug. 13, 2015
Document And Entity Information    
Entity Registrant Name Renovacare, Inc.  
Entity Central Index Key 0001016708  
Document Type 10-Q  
Document Period End Date Jun. 30, 2015  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   67,781,193
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2015  
XML 23 R18.htm IDEA: XBRL DOCUMENT v3.2.0.727
Intangible Assets - Intellectual Property (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
Impairment loss $ 10,000    
Intangible assets 152,854   $ 162,854
Other current liabilities 37,500    
Other long term liabilities $ 18,750    
Consulting expense associated with the Series A Warrant amounted 0 195,333  
Research and development costs associated with the Series A Warrant amounted 24,000 0  
Dr Gerlach [Member]      
Other current liabilities $ 50,000    
Other long term liabilities $ 150,000    
XML 24 R4.htm IDEA: XBRL DOCUMENT v3.2.0.727
CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Consolidated Statements Of Operations        
Revenue        
Expenses        
Research and development expenses $ 50,235 $ 65,000 $ 111,625 $ 65,000
General and administrative expenses 165,695 268,682 369,502 536,703
Total operating expenses 215,930 333,682 481,127 601,703
Net loss $ (215,930) $ (333,682) $ (481,127) $ (601,703)
Earnings per share - basic and diluted        
Loss per common share $ 0.00 $ (0.01) $ (0.01) $ (0.01)
Weighted average shares outstanding 66,852,595 66,575,122 66,714,122 63,575,122
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.2.0.727
Related Party Transactions
6 Months Ended
Jun. 30, 2015
Notes to Financial Statements  
Note 7. Related Party Transactions

As compensation for their service on the Board, Dr. Kirkland and Mr. Sierchio will receive an annual retainer of $6,000, payable in equal yearly installments in arrears and prorated for any partial years of service.

 

For the three months ended June 30, 2015, directors’ and consulting fees payable to officers and directors of the Company were $3,000 (2014: $3,000). Legal fees paid or payable to one of the Company’s directors in the three months ended June 30, 2015 were $28,125 (2014: $27,820). For the six months ended June 30, 2015, directors’ and consulting fees paid or payable to officers and directors of the Company were $6,000 (2014: $6,000). Legal fees paid or payable to one of the Company’s directors in the six months ended June 30, 2015 were $67,105 (2014: $82,185). Amounts included in accounts payable and accrued expenses, and due to related parties, were $23,800 at June 30, 2015 and $36,080 as of December 31, 2014.

XML 26 R11.htm IDEA: XBRL DOCUMENT v3.2.0.727
Commitments
6 Months Ended
Jun. 30, 2015
Notes to Financial Statements  
Note 6. Commitments

On August 1, 2013, the Company engaged Vector to assist the Company with identifying subject matter experts in the medical device and biotechnology industries and to assist the Company with its ongoing research, development and eventual commercialization of its Regeneration Technology (collectively, the “Services”). In consideration of the Services, the Company will pay Vector a monthly consulting fee of $5,000.

 

In connection with the Company’s anticipated Section 510(k) submission of its proprietary SkinGunTM to the Food and Drug Administration, the Company has engaged StemCell System GmbH (“StemCell Systems”) to provide it with prototypes and related documents. Pursuant to this engagement the Company incurred expenses of $44,910 in the three months ended June 30, 2015.

 

On September 25, 2014, the Company entered into a Charitable Grant Agreement with the University of Pittsburgh (the “University”), pursuant to which the Company committed to provide a charitable donation to the University in the aggregate amount of $75,000 (the “Grant”). The Company will pay the Grant in eight quarterly installments of $9,375, with the first payment made on or before October 2014 and the final payment to be made on or before July 31, 2016. Dr. Gerlach, from whom the Company purchased the SkinGunTM, is a professor at the University. At June 30, 2015, $37,500 of the amount payable to the University was recorded as current liabilities and $9,375 was recorded as long-term liabilities in the accompanying consolidated balance sheet.

 

See also “Note 7. Related Party Transactions.”

XML 27 R23.htm IDEA: XBRL DOCUMENT v3.2.0.727
Related Party Transactions (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
Accounts payable - related parties $ 23,800   $ 23,800   $ 36,080
Officers and Directors [Member] | Consulting fees [Member]          
Fees paid or due to related party 3,000 $ 3,000 6,000 $ 6,000  
Directors [Member] | Legal Fee [Member]          
Fees paid or due to related party $ 28,125 $ 27,820 $ 67,105 $ 82,185  
XML 28 R19.htm IDEA: XBRL DOCUMENT